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This thesis encompasses research towards the development of a new suite of 
conformation-specific antibodies targeting glaucoma-associated myocilin which bind both 
mouse and human myocilin, including the characterization of commercial myocilin 
antibodies, the development of antibodies specific to folded N-terminal myocilin domains, 
and the biophysical characterization of mouse myocilin olfactomedin domains. 
Chapter 1 explores the importance of antibodies to myocilin research, offering a 
brief perspective on advances in antibody development methodology and biophysical 
characterization of myocilin which will drive our development of new, conformational 
antibodies to enable detection of folded (functional) and misfolded (disease-associated) 
myocilin in tissue samples, and identification of functional binding partners. 
Chapter 2 details the testing of commercial myocilin antibodies against a variety 
of myocilin constructs to determine the epitopes recognized and conformational 
specificity. The antibodies recognize a variety of epitopes across the length of myocilin, 
binding both endogenous full-length myocilin and recombinant E. coli-expressed portions 
of human myocilin. However, they do not distinguish between folded and unfolded 
conformations of myocilin, demonstrating the need for further development of new, 
conformationally-specific myocilin antibodies.  
Chapter 3 encompasses the generation and identification of conformationally-
specific antibodies towards the N-terminal coiled-coil and leucine-zipper domains of 
myocilin. Antibody sequences from mice immunized with human and mouse N-terminal 
 
 XIII 
myocilin were selected for high affinity through phage display, then produced as antibody 
fragments to characterize their target epitope and binding properties; the most promising 
candidates were selected for further characterization in the standard and widely-applicable 
immunoglobulin-G (IgG) format. Three conformational antibodies competent for 
immunoprecipitation of endogenous human myocilin were identified, two of which bind 
myocilin’s leucine zipper and one which binds human coiled-coil. These antibodies will 
allow the broader glaucoma research community to track folded, functional N-terminal 
myocilin in mouse and human samples, assisting in identifying myocilin’s elusive function. 
Chapter 4 explores phenotypic differences between myocilin-based mouse models 
of glaucoma through the biophysical characterization of the olfactomedin domain of mouse 
myocilin, including crystal structure, melting temperatures of wild type and disease-
associated mutants, aggregation propensity and simulated aggregation of amyloid-prone 
peptide within myocilin. Human and mouse myocilin olfactomedin domains display highly 
similar structure and biophysical properties, suggesting that that – barring differences in 
cellular toxicity of aggregates – mouse and human myocilin mutants should result in 
similar glaucoma phenotypes.   
Chapter 5 provides perspective on future directions to apply the scientific 
developments detailed in the previous chapters to enhance our understanding of myocilin 
function and disfunction towards a deeper molecular understanding of both healthy and 




CHAPTER 1. ANTIBODIES USED TO DETECT GLAUCOMA-
ASSOCIATED MYOCILIN: MORE OR LESS THAN MEETS THE 
EYE?  
Sections 1.1-1.5 were adapted from “A. C. Patterson-Orazem & R. L. Lieberman, 
Antibodies used to detect glaucoma-associated myocilin: more or less than meets the eye?” 
Manuscript under review at IOVS, February 2019; submitted draft is included here.  
 
I contributed substantially to the writing of this manuscript and both designed and created 
the figure.  
 
1.1 Abstract. 
Antibodies are key reagents used in vision research, indeed across biomedical 
research, but they often do not reveal the whole story about a sample. It is important for 
researchers to be aware of aspects of antibodies that may affect or limit data interpretation. 
Federal agencies now require funded grants to demonstrate how they will authenticate 
reagents used. There is also a push for recombinant antibodies, enabled by technology 
awarded the 2018 Nobel Prize in Chemistry, which allow for thorough validation and a 
fixed DNA sequence. Here, we discuss how issues surrounding antibodies are pertinent to 
detecting myocilin, a protein found in trabecular meshwork and associated with hereditary 
glaucoma. Confirmation of myocilin expression in tissues and cell culture has been adopted 
as validation standard in trabecular meshwork research; thus, a discussion of antibody 
characteristics and fidelity is critical. Further, based on our basic structural understanding 
of myocilin architecture and its biophysical aggregation properties, we provide a wish list 
for the characteristics of next-generation antibody reagents for vision researchers. In the 
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long term, well characterized antibodies targeting myocilin will enable new insights into 
its function and involvement in glaucoma pathogenesis.  
1.2 Antibodies: important research reagents invite closer scrutiny.  
Antibodies, highly diverse proteins designed to bind specific targets and assist in 
combating infections, have been used in research to track specific target antigens across 
biomedical science since the mid-20th century [1]. Antibody biologics have also been 
transformative in their ability to treat a range of diseases [2]. At the protein level, antibodies 
consist of constant domains, similar across all antibodies, and variable domains whose 
diverse complementarity determining regions (CDRs) confer specificity to nearly any 
desired target antigen (Figure 1.1 A). Several subtypes of antibodies are commonly used 
in research; the most commonly used is immunoglobulin G (IgG). Antibodies used in 
research are designated polyclonal (pAb), monoclonal (mAb) or recombinant (rAb) based 
on their basic production method and composition. Traditional pAbs comprise a mixture 
of antibodies produced by the immune response of an animal to an antigen; the precise 
mixture varies over time and across individual animals. In contrast, mAbs consist of single 
antibody “clones” produced by a hybridoma fusion of spleen cells with an immortal 
myeloma cell line. Still tighter control of the antibody product can be achieved 
recombinantly by inserting a plasmid containing the DNA sequence encoding the desired 




Figure 1.1 Artistic rendering (not to scale) of antibody, myocilin, trabecular 
meshwork and ocular structures. (A)  Antibodies display a Y-shape, with constant 
domains at the base and variable domains at the end of the arms. (B) Myocilin forms 
a Y-shaped tetramer through its coiled-coil domains, which are attached to four C-
terminal olfactomedin structural domains by linkers. (C) The trabecular meshwork 
is composed of three structurally distinct layers of cells leading away from the lens 
and towards the Schlemm’s canal. (D) Basic anatomy of the eye.  
Although antibodies are indispensable laboratory research reagents, in general they 
are not rigorously characterized. Natural variation in animal titers leads to cross-reactivity 
and batch-to-batch variability of polyclonal antibodies, and only a low percentage of serum 
antibodies bind the intended target [3]. Even antibodies subjected to antigen affinity 
purification include a variety of antibody isotypes that target multiple epitopes with a 
variety of affinities [4]. The use of hybridomas to express monoclonal antibodies 
overcomes some of this variability but, over time, spontaneous mutations introduce a new 
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source of variability [5]. Antibody fidelity has come under scrutiny after being identified 
as the likely culprit for irreproducible studies in cancer research, resulting in NIH and other 
funding bodies requiring more rigorous validation and documentation of research reagents 
used in the lab [3, 6].       
1.3 Myocilin: associated with glaucoma yet functionally elusive. 
As a case study for how antibodies might not necessarily reveal the whole story of 
a system, we consider the case of glaucoma-associated myocilin. Wild-type myocilin 
(Figure 1.1 B) is secreted at relatively high levels to the outflow-regulating trabecular 
meshwork (TM) extracellular matrix (Figure 1.1 C) within the eye (Figure 1.1 D) [7]; the 
TM is diseased in most forms of glaucoma. At the protein level, myocilin contains multiple 
distinct domains: a N-terminal signal sequence for secretion, a structured coiled-coil region 
for multimerization, a long ~60 amino acid linker and finally, at its C-terminus, a ~250 
amino acid -propeller [8] olfactomedin (OLF) domain. In its wild-type conformation, the 
coiled-coil region confers a Y-shaped tetrameric dimer-of-dimers architecture (Figure 1.1 
B) [9]. If the explicit function of myocilin, or its binding partners, could be readily 
identified, it would have been already: despite 20 years of research effort in the community, 
there is no consensus regarding the role of myocilin in normal TM function.  
By contrast, our understanding of the role of myocilin in glaucoma is relatively 
sophisticated. Genetic mutations in myocilin, particularly within its OLF domain, are 
causative for ocular hypertension that subsequently leads to early-onset glaucoma [10]. 
Myocilin-associated glaucoma is a remarkable example of an autosomal dominant 
Mendelian inheritance pattern, with affected families harboring unique mutations 
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throughout the world. Overall, non-synonymous mutations in myocilin are responsible for 
approximately 3-5% of the 70 million open angle glaucoma cases worldwide [11]. These 
changes in amino acid sequence result in reduced OLF stability [12], protein aggregation 
and intracellular accumulation in endoplasmic reticulum (ER) [13, 14]. An anomalous 
interaction with the ER-resident molecular chaperone Grp94 [15] leads to ER stress [15-
21] and cell death [13, 17], hastening the hallmark glaucoma risk factor of increased 
intraocular pressure.  
Myocilin is not a susceptibility gene for sporadic forms of glaucoma [22], as single 
nucleotide polymorphism variants are found in control populations. However, from a 
protein perspective, it is easy to envision broader relevance of wild-type myocilin to 
glaucoma pathogenesis. Most cells deal with proteostasis-related problems – imbalances 
in protein production, trafficking, and degradation – by undergoing apoptosis. However, 
long-lived cells such as TM cells [23] are programmed to avoid cell death [24] and, 
consequently, are particularly sensitive to the accumulation of misfolded proteins [25]. 
Toxicity to long-lived cells can be triggered by environmental factors as well as 
destabilizing mutations [26]. While wild-type OLF is thermally stable when folded [27], it 
possesses an intrinsic propensity to form a misfolded precipitate of a particular kind called 
amyloid that is common to many misfolding disorders [26]. In vitro, purified OLF remains 
unchanged when incubated at 37 °C for weeks at high concentration, but aggregation is 
readily initiated by adding mimics of glaucoma-associated environmental stressors – 
including low levels of acid (pH fluctuations), peroxide (oxidative stress), mechanical 
shear (rocking), and elevated temperature [28, 29]. Even though transgenic mice 
overexpressing wild-type myocilin do not develop glaucoma [30], and overexpression 
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alone cannot drive the association of normal myocilin with Grp94 [15], myocilin driven to 
misfold by impairing cellular glycosylation interacts with Grp94, culminating in 
accumulation and toxicity observed for disease-causing variants [15]. The misfolding 
susceptibility of wild-type myocilin is further supported by histopathological studies 
demonstrating its accumulation into punctate bodies in several forms of glaucoma [31]. 
Whether accumulated wild-type myocilin contributes to TM damage and outflow 
resistance remains unknown, but it is clear that our understanding of wild-type myocilin 
function and dysfunction remains blurry. 
1.4 Myocilin antibodies: we don’t know what we cannot detect. 
Limitations of the reagents vision scientists have been using to detect myocilin in 
primary cell culture and tissue samples necessarily affect our contextual understanding of 
myocilin. For example, early in myocilin research there were reports of an apparent 66 kDa 
isoform, which was visible by Western blot using multiple myocilin antibodies [28, 32], 
but was not consistently observed. The jury is still out regarding this 66 kDa species, but it 
has not been confirmed as myocilin by mass spectrometry [29, 33], and may instead be a 
closely sequence-related protein [34] or serum albumin [29]. Myocilin protein expression 
in TM tissue and cell culture has been adopted as validation standard for the research 
community [7], elevating the need for transparent evaluation of antibody reagents available 
for the community to use. 
Recently, we reported that commercially-available myocilin-directed antibodies 
now used in vision research target epitopes distributed across the protein [35], but do not 
differentiate among folded and misfolded states. Thus, at minimum, we are currently 
 
 7 
missing information about whether myocilin is properly folded or whether it is adopting a 
disease state in a given sample. Even without destabilizing mutations, we know myocilin 
is very sensitive to its chemical environment. Beyond OLF being driven to misfold upon 
exposure to environmental stressors discussed above [36, 37], higher order oligomeric 
states beyond the native tetramer [9], mediated by disulfide bonds at the far N-terminal 
before the coiled-coils but after its signal sequence, have been detected in several 
experiments [38, 39]. Based on functional studies of olfactomedin family members, all of 
which contain eponymous OLF domains, post-translational modifications and protein-
protein interactions are relevant to antibody detection. Cleavage of myocilin has been 
detected in mammalian cell culture [40], in line with a functional feature of other 
olfactomedin family members [41-43]. This feature has not been observed in tissue samples 
containing myocilin, however, likely because the antibodies used to stain for myocilin only 
detect one of the cleavage products. Other posttranslational modifications such as 
phosphorylation or glycosylation may also impede antibody binding, leading to the 
conclusion that myocilin is not present when it is simply not detectable. Additionally, other 
olfactomedin family members are known to function through complex macromolecular 
assemblies – such interactions between latrophilin OLF and a leucine-rich repeat protein 
which help modulate contacts between nerve cells [44]. On the other hand, the N-terminal 
coiled-coil domains of myocilin are “sticky” and predicted to interact with other 
extracellular matrix proteins [9]. These features of myocilin demand further elucidation, 
but also experimental consideration including, but not limited to, not relying on any single 




1.5 The future of myocilin-directed antibodies: our wish list. 
To develop the most effective and reliable antibody reagents, consideration of the 
molecular properties of both antigens and antibodies is key. Understanding how an 
antibody interacts with its target antigen allows researchers to engineer antibodies for their 
own purposes, using a selection of epitopes enlightened by our structural understanding of 
the antigen. In addition, high-throughput and efficient in-vitro methods are now available 
to identify, design and optimize identified antibodies. Indeed, the 2018 Nobel Prize in 
Chemistry shared by Arnold, Smith, and Winter recognizes contributions to the directed 
evolution and phage display strategies, which represent landmark developments in protein 
engineering methodology directly applicable to antibodies.  
Knowledge of myocilin structure and misfolding should facilitate the development 
of new antibody tools to study the protein in unprecedented detail. Ideal antibodies would 
harbor the following characteristics: (a) detect a variety of unique epitopes throughout the 
myocilin protein (b) be conformationally specific to a well-defined state of myocilin 
(folded, misfolded) (c) be recombinant to enable high quality control standards maintained 
by DNA sequencing [6] and not constitute a limited reagent, and (d) harbor cross-reactive 
for myocilin from multiple species, to streamline antibody use in the vision research 
community.  
Beyond their application in validating primary human TM cells and tissues [7], a 
new suite of antibodies targeting deliberate molecular aspects of myocilin would reveal 
currently inaccessible specifics of myocilin in any given research sample of interest. Such 
information should lead to a better understanding of myocilin in normal physiology, as 
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well as the role of myocilin misfolding in normal eye aging, glaucoma, and possibly other 
scenarios in the body.  In turn, the community will develop a more nuanced molecular 
picture of the TM, a complex and fascinating eye tissue that is regularly subjected to 
numerous chemical and biomechanical insults, unveiling new targets for anti-glaucoma 
therapies.  
1.6 Contributions to the future of myocilin antibodies in research.  
In this thesis, concerns regarding the quality and properties of existing myocilin 
antibodies are addressed first (Chapter 2) by identifying the target epitope and 
conformational specificity of four commercial myocilin antibodies used in the literature. 
This study provides a more thorough understanding of available myocilin antibodies such 
that researchers are aware of, including 1) the specific portion of myocilin detected, 2) 
potential non-specific binding interactions observed and 3) that none of these antibodies 
distinguish between folded and unfolded myocilin. 
To afford new functionality in myocilin antibodies, conformational antibodies 
specific to folded N-terminal domains of myocilin were developed which are both 
recombinant and cross-reactive to human and mouse myocilin (Chapter 3). Recent 
advances in myocilin structure were combined with established antibody engineering 
technologies allowing in-vitro selection of antibody sequences from immunized mice 
which were then characterized for affinity to mouse and human myocilin, target epitope 
and conformational specificity. Three new conformational antibodies – two targeting 
mouse and human LZ, one targeting human CC – are competent for immunoprecipitation 
of folded endogenous TM-secreted myocilin from primary TM cells and are now available 
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to track the localization of folded N-terminal myocilin in tissue samples and for application 
to immunoprecipitation-shotgun proteomics approaches to identify functional myocilin 
binding partners. 
Lastly, to inform the future development of C-terminal OLF-targeting antibodies to 
folded and misfolded mouse myocilin, and additionally to elucidate potential discrepancies 
in myocilin-based mouse models of glaucoma due to differences in the biophysical 
properties of mouse OLF, the structure and aggregation of mouse OLF was biophysically 
characterized (Chapter 4). Human and mouse OLF display largely similar properties in 
terms of structure, stability and aggregation which can be applied to generation of new 
antibodies specific only to folded or only to misfolded OLF and which can be used to 
further elucidate myocilin function and dysfunction in both humans and mouse models.  
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CHAPTER 2. EPITOPE MAPPING OF COMMERCIAL 
ANTIBODIES THAT DETECT MYOCILIN. 
Adapted from “A.C. Patterson-Orazem, S. E. Hill, M. P. Fautsch & R. L. Lieberman; 
Epitope mapping of commercial antibodies that detect myocilin; Experimental Eye 
Research, 2018” [35]. Reproduced with permission from Elsevier. 
 
I contributed to the work in this chapter in design,execution and analysis of antibody 
characterization experiments, design and execution of figures, and the writing and editing 
of the paper. S. E. Hill contributed N-terminal myocilin constructs, experimental design, 
figure design, and editing of the paper. M. P. Fautsch contributed antibodies developed in 
his lab and paper editing. R. L. Lieberman contributed to the experimental design, figure 
design, and paper crafting, writing and editing.  
2.1 Abstract. 
The presence of myocilin is often used in the process of validating trabecular 
meshwork (TM) cells and eye tissues, but the antibody reagents used for detection are 
poorly characterized. Indeed, for over a century, researchers have been using antibodies to 
track proteins of interest in a variety of biological contexts, but many antibodies remain ill-
defined at the molecular level and in their target epitope. Such issues have prompted efforts 
from major funding agencies to validate reagents and combat reproducibility issues across 
biomedical sciences. Here we characterize the epitopes recognized by four commercial 
myocilin antibodies, aided by structurally and biochemically characterized myocilin 
fragments. All four antibodies recognize enriched myocilin secreted from human TM cell 
media. The detection of myocilin fragments by ELISA and Western blot reveal a variety 
of epitopes across the myocilin polypeptide chain. A more precise understanding of 
myocilin antibody targets, including conformational specificity, should aid the community 
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in standardizing protocols across laboratories and in turn, lead to a better understanding of 
eye physiology and disease.  
2.2 Introduction. 
Antibodies, protein molecules derived from the immune response in animals, are 
powerful scientific and therapeutic reagents due to their ability to strongly and specifically 
bind a desired target antigen. Polyclonal antibodies have been used for over a century and 
monoclonal antibodies from hybridoma cell lines for decades [45]. Although antibodies 
have been indispensable in addressing research questions across the biomedical sciences, 
these reagents are generally not rigorously characterized and are thus of variable quality 
[6, 46]. Polyclonal antibodies are notorious for problems with cross-reactivity and batch-
to-batch variability due to natural variation in animal titers [47]. Only 0.5-5% of the 
antibodies in a polyclonal antibody sample bind their target protein [3, 4, 48], and even 
antibodies purified by using an antigen affinity step may include a variety of antibody 
isotypes targeting multiple epitopes with a variety of affinities [4]. The use of hybridomas 
to express monoclonal antibodies overcomes some of this variability [49]. However, over 
time, hybridomas can undergo mutations that alter specificity, thus introducing a new 
source of variability [5]. The rigorous validation of research reagents, including of 
antibodies, has become a high priority for NIH and other funding bodies due to the 
multitude of research studies that cannot be independently replicated [50].  
Vision researchers who study trabecular meshwork (TM) rely on antibodies to 
detect myocilin, a protein secreted from TM cells [27, 51] and associated with heritable 
glaucoma [10]. Namely, myocilin expression is often used to distinguish TM cells and 
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tissues from other anterior segment regions [52, 53]. Our lab recently characterized the 
structural regions of myocilin (Figure 2.1 A, B) including the N-terminal coiled-coil 
domains by solution X-ray scattering, chemical crosslinking, and X-ray crystallography 
[9], and the C-terminal β-propeller olfactomedin domain (OLF) by X-ray crystallography 
[8]. Our studies reveal that myocilin is a Y-shaped dimer-of-dimers (Figure 2.1 B) [9]: the 
N-terminal coiled-coil region (CC, residues 33-111) forms a tetrameric stem with 
disulfides at Cys47 and Cys61, and the leucine-zipper (LZ, residues 112-185), a special 
type of coiled-coil, forms two dimeric arms, each of which is stabilized by a C-terminal 
disulfide bond [9]. Finally, a ~60 residue linker connects the LZ to two pairs of monomeric 
OLF domains (Figure 2.1 B).  
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Currently, there are several commercially-available antibodies against myocilin, 
but little is known about the epitope(s) recognized and specificity for detecting myocilin in 
the context of the (extra)cellular milieu. Knowledge of epitopes detected by these 
antibodies is important for several reasons. First, cleavage of myocilin has been reported 
in mammalian cells [40], like for other olfactomedin family members latrophilin [41] and 
gliomedin [42, 43] where such cleavage is functional. Using a single antibody reagent to 
detect myocilin may not fully describe its whereabouts or function, especially if cleavage 
is functional. Related, not all epitopes may be accessible to myocilin in a functional 
context, for example, in the case of complexation with a binding partner or upon post-
translational modification. Second, the OLF domain of myocilin can be driven to misfold, 
Figure 2.1 Introduction to myocilin structure, commercial antibodies, and protein 
constructs tested. (A) Gene structure depicting the domains of myocilin, including 
signal peptide (SP), location of key cysteine residues (C47, C61 and C185) and its 
coiled-coil (CC), leucine zipper (LZ) and olfactomedin (OLF) domains. (B) Myocilin 
quaternary structure based on solution X-ray scattering, X-ray crystallography and 
chemical cross-linking experiments. (C) Identifying information for commercial 
myocilin antibodies selected for this study, including antigen used for antibody 
development, clonality, and currently advertised epitope. (D) Myocilin constructs 
used in this study represent a combination of shorter and longer myocilin fragments. 
Each potential epitope for antibody recognition is represented at least twice. 
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even in the absence of destabilizing disease-associated mutations, with selected 
environmental stressors [36, 37]. Indeed, the overall oligomeric state of myocilin may be 
sensitive to its environment, as higher-ordered states of myocilin, mediated by disulfide 
bonds, have been detected in several experiments [38, 39]. Detailed knowledge of epitope 
and conformational specificity of antibodies against myocilin could be transformative in 
our understanding of the functional role of myocilin processing, oligomerization, and 
misfolding.  
Here, we took advantage of the well-defined domain constructs our lab used for 
structural studies of myocilin to characterize four anti-myocilin antibodies from 
commercial vendors (Ab#1-Ab#4). We describe the specific amino acid epitope within 
myocilin recognized by the four reagents, the conformational specificity of the respective 
epitope, and, to the extent possible, cross-reactivity (Figure 2.1 C). Ab#1 (Abcam Cat# 
ab41552, RRID:AB_776605) is a rabbit polyclonal antibody raised against recombinant 
myocilin residues 25-46 conjugated to keyhole limpet hemocyanin (KLH) and purified by 
protein A affinity chromatography. This antigen includes several residues within the signal 
peptide (residues 1-33), cleaved prior to secretion [54], and far N-terminal residues without 
predicted structure. Ab#2 (Millipore Cat# MABN866, RRID:AB_2721107) is a mouse 
monoclonal antibody raised against myocilin residues 33-504 produced in TM5 cells with 
C-terminal V5 and hexa-histidine (6x-His) tags. This antibody was purified from mouse 
hybridoma culture supernatant by protein A/G affinity chromatography and its epitope was 
previously localized to residues 33-214 within N-terminal myocilin [34]. Ab#3 (R&D 
Systems Cat# MAB3446, RRID:AB_2148649), is also an affinity-purified monoclonal 
mouse antibody, raised against recombinant myocilin (residues 33-504) that was produced 
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in the mouse myeloma cell line NS0. Finally, Ab#4 (Santa Cruz Biotechnology Cat# sc-
137233, RRID:AB_2148737) is a monoclonal mouse antibody raised against recombinant 
myocilin residues 240-370 (cell line unspecified), a predominantly internal sequence of the 
C-terminal OLF structural domain, which spans residues 245-504 [8].  
2.3 Materials and Methods.  
2.3.1 Production of recombinant protein constructs. 
Cell pastes containing recombinant proteins were gathered from S. E. Hill (all N-
terminal myocilin constructs), D. J. E. Huard (control), I. M. Dominic (linker region) and 
A. C. Patterson-Orazem (C-terminal). Cell lysates and purified proteins were prepared by 
A. C. Patterson-Orazem. Recombinant myocilin subdomains (Figure 2.1 D) were cloned 
and expressed in E. coli, and purified as previously described [9, 55]. The linker region 
between the LZ and OLF domains (residues 185-244) was cloned into pET-28b vector with 
N-terminal 6x-His and S-tags (Genscript). The plasmid containing the linker region was 
transformed into E. coli BL21(DE3)pLysS, grown in Terrific Broth (Fisher) and expression 
was induced at OD600=0.8 with 1 mM isopropyl-β-D-thiogalactopyranoside for 3 hours at 
37 °C. Cell lysates were prepared by gently resuspending 0.5 g cells in 2.5 mL HBS (50 
mM Hepes (pH 7.5), 200 mM NaCl, 10% glycerol) and 1/10 Complete EDTA-Free 
Protease Inhibitor Cocktail tablet (Roche), lysed by sonication, clarified by centrifugation 




2.3.2 Enrichment of endogenous hTM-secreted myocilin. 
Enrichment of endogenous hTM-secreted myocilin was conducted by E. Nguyen. 
Human TM (hTM) cell medium was a kind gift from E. Snider and C. R. Ethier [56]. To 
enrich secreted myocilin from these samples, 20 mL of conditioned hTM medium was 
purified by heparin affinity (1-mL HiTrap Heparin HP, GE Healthcare) employing 
phosphate-buffered saline (10 mM Na2HPO4, 1.8 mM KH2PO4, 130 mM NaCl, 2.7 mM 
KCl, 10% glycerol, PBS) and an elution gradient to 1 M NaCl across 80 column volumes. 
Myocilin, detected by Western blot using the polyclonal anti-myocilin antibody N-15 
(Table 3.1, RRID:AB_2148741, no longer commercially available), eluted at 
approximately 0.4 M NaCl. Corresponding fractions were pooled and concentrated 
approximately 36-fold using an Amicon Ultra centrifugal filter with 30 kDa molecular 
weight cut-off.  
2.3.3 Western blots and ELISA. 
Western blots and ELISA were conducted by A. C. Patterson-Orazem. Western 
blots were conducted on 25-100x dilutions of clarified E. coli cell lysates or 5 µL heparin-
enriched hTM myocilin and transferred from SDS-PAGE to polyvinylidene difluoride 
membranes (Millipore) by standard electrophoresis methods. Primary antibodies were used 
at either 1 µg/mL or the manufacturer-recommended concentration, followed by 1:2000 
dilution of secondary antibody: goat anti-mouse (Thermo Fisher Scientific Cat# 62-6520, 
RRID:AB_2533947) or goat anti-rabbit (KPL, Cat# 074-1506, RRID:AB_2721169). Blots 
were imaged using an Amersham Imager A600 (GE Healthcare). Western blot results 
represent at least two biological replicates per antibody tested. For a given antibody tested 
 
 18 
in ELISA, triplicates of all proteins samples were immobilized on one medium-binding 96-
well Costar plates (Corning) by overnight 4 °C incubation of 50 µL/well 2x diluted cell 
lysate in HBS (with non-myocilin cell lysate as negative control), or 1-5 µM purified 
protein [9, 55], employing antigen-free wells as a control. Samples were treated with serial 
dilutions of primary antibody (starting from 5 µg/mL) and 1:2000 dilutions of appropriate 
secondary antibody. Absorbance of HCl-quenched 3,3’,5,5’-tetramethylbenzidine (TMB, 
450 nm) was measured using a BioTek Synergy 2 plate reader. ELISA results are an 
average of at least two biological replicates per antibody tested. Absorbance values for 
each ELISA plate were normalized to the maximum absorbance within that plate, then 
multiple, normalized plates were averaged and plotted in Origin Professional 2016. Error 
bars represent standard deviation across all samples.  
2.4 Results and Discussion.  
Ab#1 primarily recognizes the far N-terminal residues of myocilin (residues 33-
46), but a secondary epitope and other non-specific bands are also detected. In Western 
blot, Ab#1 recognizes recombinant human myocilin comprising residues 33-226 (rMyoc33-
226, Figure 2.2 A) and secreted full-length myocilin from hTM media (Figure 2.2 B). Over-
exposure of Western blots results in detection of endogenous proteins from the E. coli cell 
lysate (not shown) as well as weak bands ~70 and 100 kDa in the hTM sample (Figure 2.2 
B). A “66 kDa myocilin isoform” has been detected by multiple myocilin antibodies [27, 
28] but has fallen under suspicion due to poor reproducibility. The 66 kDa band has yet to 
be confirmed as myocilin by mass spectrometry [29, 33], but it has been speculated that 
this band may instead comprise sequence-related proteins [34] or albumin [29]. In Western 
blot (Figure 2A) and ELISA (Figure 2.2 C), Ab#1 also recognizes the smaller far-N-
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terminal tetrameric construct composed of residues 33-111 (rMyoc33-111). Thus, of the 
residues within the antigen for Ab#1 (25-46), residues 33-46 are sufficient for detecting 
larger myocilin constructs containing these residues. Ab#1 also weakly recognizes the 
construct composed of residues 69-185 (rMyoc69-185) in ELISA (Figure 2.2 C) and in over-
exposed Western blots (not shown). This could arise from two segments within this 
construct (residues 102-109 and 158-168), which share 75 and 81% sequence similarity, 
respectively, with the antigen. This weak interaction likely benefits from the increased 
avidity of tetrameric rMyoc69-185 in ELISA. 
Ab#2 recognizes an epitope within rMyoc33-111, and its detection is sensitive to the 
presence of disulfide bonds formed by C47 and C61. In Western blot, Ab#2 detects E. coli 
lysates containing rMyoc33-226 and rMyoc33-111 (Figure 2.2 D) as well as secreted hTM 
myocilin (Figure 2.2 E). In initial ELISA experiments, Ab#2 detected rMyoc33-226 and, to 
a lesser extent, rMyoc33-111 (not shown). These results were reproduced in a follow-up 
ELISA experiment conducted using equimolar concentrations of purified recombinant 
rMyoc33-226 and rMyoc33-111 (Figure 2.2 F). To test the contribution of disulfide bond 
formation to the recognized epitope given previously characterized variations in E. coli 
disulfide bonding for rMyoc33-226 and rMyoc33-111, ELISA was also conducted on the 
purified disulfide-disrupted variant rMyoc33-226 C47S/C61S (rMyoc33-226 (C47S/C61S)) [9], 




Figure 2.2 Epitope mapping of commercial antibodies reveals four distinct epitopes. 
(A,D,G,J) Western blots demonstrate binding of antibodies against cell lysates 
containing recombinant myocilin fragments under denaturing conditions. 
Manufacturers’ recommended primary antibody concentrations are indicated with 
an asterisk, and standards (PageRulerTM Plus, Thermo Scientific) are indicated in 
kilodaltons. (B,E,H,K) All antibodies tested recognize myocilin enriched from hTM 
cell-conditioned medium in Western blots. ELISA conducted against clarified cell 
lysates (C,I) and purified protein (F,L) demonstrate antibody binding to recombinant 
myocilin constructs in native conditions. (M) Schematic representation of target 
regions of the four commercial antibodies on myocilin. 
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Ab#3 recognizes the LZ region (residues 112-185) of myocilin. This antibody 
recognized rMyoc33-226 (Figure 2.2 G) and hTM-secreted full-length myocilin (Figure 2.2 
H) in Western blots, and rMyoc33-226 in ELISA (Figure 2.2 I). Both Western blot and ELISA 
yield robust recognition of smaller N-terminal constructs, corresponding to residues 69-
185 (rMyoc69-185) and the LZ-containing subdomain 112-185 (rMyoc112-185).  
Ab#4 recognizes the myocilin OLF domain, as designed (Figure 2.2 C) but does 
not distinguish between natively folded and misfolded states. In Western blot, Ab#4 detects 
the purified OLF domain (Figure 2.2 J) as well as full-length secreted hTM myocilin 
(Figure 2.2 K). In ELISA (Figure 2.2 L), Ab#4 recognizes both folded OLF monomer and 
amyloid-like misfolded OLF comprising residues 228-504 (rMyoc228-504), expressed and 
purified from E. coli as a maltose-binding protein (MBP) fusion [37]. Notably, we 
previously showed that the polyclonal precursor to this antibody (Santa Cruz H-130, no 
longer available) recognizes related domains from other olfactomedin family members 
[57], which share a conserved interior [8], suggesting that this antibody may be similarly 
non-selective.  
 In sum, our study reveals that the commercial myocilin antibodies tested recognize 
amino acid sequence-derived epitopes across myocilin structural domains (Figure 2.2 M), 
including far N-terminal (residues 25-46, Ab#1), CC (residues 33-111, Ab#2), LZ (residues 
112-185, Ab#3) and C-terminal OLF domain (residues 240-370, Ab#4). All four antibodies 
recognize myocilin secreted from hTM media; however, Ab#1 also exhibits non-specific 
binding to other proteins at high exposures. The diversity of epitopes revealed by our in 
vitro ELISA and Western blot experiments suggest that biological insights may be gleaned 
from employing different antibodies to detect the same myocilin-containing tissue sample. 
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Such comparative tissue studies could assess the accessibility of a given epitope, tying into 
protein function, processing, or misfolding. Conversely, by using a single myocilin 
antibody to a given epitope, functionally relevant myocilin fragments may remain 
undetected or non-myocilin contaminants may be inadvertently detected. Our library of 
recombinant myocilin constructs will be useful to monitor changes in epitope recognition 
by myocilin antibodies over time and from lot-to-lot. Finally, beyond the currently 
available myocilin antibodies, we anticipate that the TM research community may benefit 
from recombinant antibodies [6]. Such antibodies can be held to higher quality control 
standards due to gene sequencing, and can be tailored by engineering for sensitivity, 




CHAPTER 3. RECOMBINANT ANTIBODIES OFFER 
CONFORMATION-SPECIFIC TARGETING OF THE N-
TERMINAL COILED-COILS OF GLAUCOMA-ASSOCIATED 
MYOCILIN.   
Adapted from “A. C. Patterson-Orazem, A. Qerqez, S. E. Hill, Y. Ku, J. A. Maynard & R. 
L. Lieberman, Recombinant antibodies offer conformation-specific targeting of the N-
terminal coiled-coils of glaucoma-associated myocilin,” a manuscript in preparation for 
submission.   
 
I contributed to experimental design for antibody development and characterization, and 
conducted experiments including epitope mapping of candidate antibodies, dot blots and 
Western blots to assess conformational specificity, dot blots against enriched endogenous 
myocilin, immunoprecipitation of endogenous myocilin and IgG thermal stability 
measurements. I additionally designed and executed figures (for Figure 2, execution only) 
and contributed to the organization, writing and editing of the manuscript.  
 
A. Qerqez contributed to antibody-directed experimental design, phage display, scAb and 
IgG expression and purification, ELISA experiments with purified scAbs and IgGs, and 
designed Figure 2. S. E. Hill provided N-terminal myocilin constructs, prepared proteins 
for mouse immunizations, and assisted in myocilin-directed experimental design. Y. Ku 
conducted replicate western blot, dot blot and immunoprecipitation experiments, Image J 
analyses for heat maps, and assisted in manuscript editing. J. A. Maynard contributed 
antibody-directed experimental design; R. L. Lieberman contributed overall experimental 
design and to editing this manuscript. 
3.1 Abstract.  
Recombinant antibodies with well-characterized epitopes and known 
conformational specificity are key reagents for robust interpretation and reproducibility of 
immunoassays across biomedical research. For glaucoma-associated myocilin, recent 
developments in our understanding of its unique branched architecture and aggregation 
indicate that epitopes recognized by myocilin-directed antibodies used currently in the field 
do not differentiate among numerous disease-associated states of the protein, limiting 
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insight. Here, we used protein engineering methods to develop new recombinant antibodies 
that detect the N-terminal coiled-coil and leucine-zipper structural domains of myocilin. 
We identified two leucine-zipper-directed antibodies that detect human and mouse 
myocilin. Both are competent for immunoprecipitation of secreted myocilin from spent 
media of primary human trabecular meshwork cells. One of these antibodies preferentially 
detects folded myocilin and thus is conformationally selective. A third antibody, directed 
to the human coiled-coil, is conformationally selective and competent for 
immunoprecipitation of endogenous myocilin.  The availability of these new antibodies 
offers unique opportunities to visualize and characterize murine and human myocilin in 
unprecedented detail. 
3.2 Introduction. 
Antibodies are indispensable and ubiquitous tools for targeting a specific antigen 
across biomedical research. Advances in antibody engineering methodology [58] and 
concerns over reproducibility of antibody reagents [3] are fueling a movement towards 
highly characterized recombinant antibodies [6] which avoid the batch-to-batch variability 
of traditional polyclonal antibodies [47] and the genetic drift of traditional monoclonal 
antibodies [5]. These new antibodies can be designed with the structure, function and 
dysfunction of their targets in mind – including conformationally-specific antibodies 
targeted, for example, to amyloid [59] and other misfolded proteins [60] with uses ranging 
from structural and mechanistic characterization to potential therapeutic applications. 
Myocilin is a multi-domain protein (Figure 3.1 A) highly expressed in the 
trabecular meshwork (TM) [27, 51], an ocular tissue in the anterior segment involved in 
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the filtration of aqueous humor and therefore the regulation of intraocular pressure (IOP), 
[52] the causal risk factor for vision loss in glaucoma , a disease estimated to affect ~65 
million people worldwide by 2020 [61]. Destabilizing mutations in myocilin [10, 62] result 
in hereditary primary open-angle glaucoma. Mutant myocilin aggregates and accumulates 
intracellularly, leading to cell death, reduced TM outflow, hastening the timeline for 
glaucoma-associated IOP elevation and vision loss [63]. While the biological function of 
myocilin in TM still remains elusive, increased myocilin expression due to glaucoma-
relevant stressors such as steroid treatment [51] and mechanical stretching [64] suggest 





Figure 3.1 Introduction to myocilin structure and constructs. A. Myocilin gene 
sequence includes a N-terminal signal peptide (SP), coiled-coil (CC) and leucine-
zipper (LZ) structural domains and a C-terminal olfactomedin domain (OLF). B. 
Model of myocilin architecture based on SEC-SAXS, X-ray crystallography and 
chemical crosslinking. C. Table of myocilin constructs used in this paper. Amino acids 
for recombinant proteins shown in parenthesis. 
Myocilin antibodies are used to track the protein in a variety of human samples and 
animal models, as well as validate TM cell lines [65], Recently, we tested the commercial 
myocilin antibodies recommended by the TM research community [65] to clarify the 
specific epitopes targeted [35]. These antibodies recognized several epitopes across the 
myocilin protein, but were unable to distinguish between folded and misfolded forms, 
which are disease-relevant [35]. Thus, antibodies used to study myocilin are contributing 
to the still-blurry functional picture. Lack of conformational selectivity limits insight 
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gained from TM studies as myocilin is prone both to amyloid aggregation [36, 37] and 
proteolysis [66, 67].  
Here we leverage our understanding of myocilin structure to develop new 
antibodies. We targeted the N-terminal tetrameric coiled-coil domain and dimeric leucine-
zipper domain (Figure 3.1 B).  Our new antibodies are recombinant, which allows for DNA 
sequence confirmation, unlimited production via cell culture, and facile conversion to other 
formats (IgG, Fab). They are also cross-reactive, binding human and mouse myocilin 
(~80% sequence identity) to streamline lab reagents. Finally, their sensitivity to the 
conformational state of myocilin is well-defined.  
Materials and Methods. 
3.2.1 Commercial Antibodies Used 
Table 3.1 Commercial antibodies used in antibody development and testing. 
  
Antibody Identification Epitope & Clonality 
Commercial anti-LZ 
R&D Systems Cat# MAB3446  
RRID: AB_2148649 
human myocilin LZ 
within residues 112-185 
(monoclonal) 
Mouse anti-His 4A12E4 




M13 RL-ph1*HRP  
Santa Cruz Cat #sc-53004 
RRID: AB_673750 
M13 phage coat protein 
(monoclonal*HRP) 
Mouse anti-Myc 9E10 
Santa Cruz Cat #sc-40 
RRID:AB_627268 








Goat anti-human κ*HRP 
Southern Biotek Cat# 2060-05 
RRID: AB_619883 
human kappa light chain 
(polyclonal*HRP) 
Antibody conjugation indicated by *; clone designations are italicized. 
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3.2.2 Protein expression and purification: myocilin  
N-terminal myocilin constructs, designed by S. E. Hill, were expressed and purified 
by S. E. Hill and A. C. Patterson-Orazem. Clarified cell lysates were produced by A. C. 
Patterson-Orazem and Y. Ku. N-terminal myocilin fragments (see Figure 3.1 C) were 
expressed in E. coli BL21-DE3-pLysS using pET-30 XaLIC [9] or in pMAL (hNTD, 
comprising residues 33-226, only) [35] vectors. Proteins were purified as described 
previously [9] by nickel affinity chromatography followed by size-exclusion on AKTA 
Pure or Purifier (GE).  For immunization and panning, expression tags were cleaved using 
Factor-Xa (New England Biolabs) and purified proteins isolated by heparin affinity and 
size-exclusion chromatography. Protein concentrations were determined by absorbance at 
280nm using ExPaSy-predicted extinction coefficients, as described previously [9].  
Our intent was to immunize mice with hCCLZ (comprising residues 69-198) and 
boost with the orthologous mouse construct mCCLZ (residues 55-171). However, post 
immunization, we learned that during purification our mCCLZ construct was cleaved by 
Factor Xa at a fortuitous site (TLGR92) [9]. Thus, the actual immunogen used was mLZ 
(residues 93-171). Similar secondary sites have been reported in literature exploring 
Factor-Xa specificity [68, 69].  
For dot blot characterization, clarified cell lysates were prepared by sonicating 0.2g 
cell paste in 1 mL buffer (50mM HEPES (pH 7.5), 200mM NaCl, 10% glycerol) until 
clarified, then removing the insoluble fractions by centrifugation at 17,000 x g [35]. Cell 
lysates used for the negative control were derived from BL21-DE3-pLysS cells expressing 
a non-myocilin protein with both tags present in the N-terminal constructs used here. Full-
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length endogenous myocilin was enriched from spent hTM medium by heparin affinity, 
also as described previously [35]. 
3.2.3 Mouse Immunization & RT PCR  
 Immunizations were conducted by J.M. Hyun, RNA extraction and cDNA storage 
by A. Qerqez (Maynard Lab, U. T. Austin). All protocols were approved by the University 
of Texas at Austin IACUC, and all mice were handled in accordance with IACUC 
guidelines. Three 6 week old BALB/c mice were immunized subcutaneously with 5mg of 
hCCLZ using Freund’s adjuvant. Four weeks later, the mice were bled through a tail vein 
and boosted subcutaneously with 5 mg of mLZ using incomplete Freund’s adjuvant. Mice 
were then sacrificed and their spleens were harvested and stored in 1mL RNAlater solution 
at -80°C. Blood collected was used in an ELISA to determine the serum antibody titers 
against hCCLZ and mLZ. Total RNA was extracted from frozen spleens with TRIzol 
(Invitrogen) and the PureLink RNA kit (Invitrogen) according to the manufacturers’ 
instructions. Concentration of RNA was determined using a NanoDrop2000 (Thermo 
Scientific). RNA was stored at -80°C until further use. For first strand cDNA synthesis, a 
total of 500 ng of RNA was used. First strand cDNA synthesis was performed using the 
SuperScript IV Transcriptase (Invitrogen) kit following the manufacturer’s instructions. 
cDNA was then stored at -20°C until further use.  
3.2.4 Phage Display Library Construction  
 Phage display libraries were constructed by A. Qerqez, Maynard Lab at U. T. 
Austin. The cDNA was then used to generate variable heavy (VH) and variable light (VL) 
chain repertoires for each mouse using the primer sets and PCR conditions described 
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previously [70]. The VH and VL fragments were then used as a template (30 ng of each) for 
the overlapped PCR [70] to generate VL-linker-VH fragments (scFv). The overlapped PCR 
fragments (about 10 μg per mouse scFv) were gel purified using Zymoclean Gel DNA 
Recovery kit and then digested using SfiI restriction enzyme (New England BioLabs) 
overnight at 50°C. About 50 μg of freshly purified pMopac24 vector was also digested 
overnight using SfiI at 50°C. The digests were gel purified and cleaned using Zymoclean 
Gel DNA Recovery kit.  Ligation between the two fragments was performed using T4 
DNA ligase (New England BioLabs) (400 - 500 μL ligations per mouse) and was left at 
16°C overnight. The next morning (after 16-18 hours), the ligation was heat inactivated for 
20 minutes at 65°C and all ligations were pooled together and concentrated using n-butanol 
by tenfold. The concentrated ligation was then desalted using nitrocellulose membranes for 
two hours before electroporating in freshly prepared XL1Blue electrocompetent cells (30 
to 40 electroporations). The electroporations were recovered in warm SOC medium for 1 
hour before plating on medium 2XYT agar plate with 1% glucose and 100 ug/mL 
ampicillin plates. An aliquot was 10-fold serially diluted and plated to count library size. 
Plates are left overnight at room temperature and then scraped the next morning into 2XYT 
medium with 1% glucose. The scraped bacteria was pooled to form the master library, then 
frozen down in 1 mL aliquots at -80°C at an OD600 of 5. 
3.2.5 Phage Production, Purification, & Panning  
 Phage display was conducted by A. Qerqez (Maynard Lab, U. T. Austin). One 
aliquot from the library was thawed and used to inoculate a 30 mL 2XYT culture 
supplemented with 1% glucose and 100 ug/mL ampicillin at a starting OD600 of 0.08-0.1. 
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The flask labeled “input” was then grown at 37°C shaking at 225 RPM for 2-3 hours until 
the OD600 was between 0.4 and 0.6. 1mM final IPTG concentrated as well as M13KO7 
helper phage at a multiplicity of 20. The flask was allowed to shake an additional 20 to 30 
minutes at 37°C and then the temperature is switched to 25°C. Three hours after adding the 
helper phage, the culture was supplemented with 25 ug/mL kanamycin and allowed to 
shake overnight at 25°C. Phage were then purified from the supernatant of the culture using 
1/5th volume of precipitation solution (2.5M NaCl and 20% PEG-8000). Phage 
concentration was assessed using phage forming units (pfu) with serially diluted phage 
added to mid-log phase XL1Blue cells. These dilutions were then plated on 2XYT agar 
plate with 1% glucose and 100 ug/mL ampicillin.  
 The first round of panning was performed using mouse anti-Myc 9E10 (Table 3.1, 
RRID: AB_627268) as bait to remove any clones with possible stop codons. The 
subsequent rounds were panned against hCCLZ or mLZ. For panning, the protein was 
coated on eight ELISA plate wells (Costar) and allowed to incubate at 2 - 4 ug/mL 
overnight at 4°C. The following day the plates were blocked using 5% milk + 1x PBST for 
1 hour. Another non-coated plate was blocked with 5% milk (8 wells). Once the phage was 
purified from the culture’s supernatant, it was resuspended in a 1:1 ratio in 10% milk and 
then aliquoted across 8 wells of non-coated but blocked plate and allowed to incubate at 
room temperature on a rocker for 1 hour. This ensures that any milk binding proteins are 
removed and do not propagate during the panning. The milk and phage mixture is then 
added to the antigen bound plate and allowed to incubate for 2 hours. Finally, the wells are 
washed rigorously using sterile PBS plus 0.1% Tween-20 and bound phage are eluted using 
0.1 M glycine at pH of 2.5, pooled, and then neutralized with 24 uLs of 2 M Tris-HCl (pH 
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of 8.0). Half of the output phages were added to mid-log phase XL1Blue culture and 
incubated for 30 minutes shaking at 37°C. The input growth process was repeated for 
subsequent rounds of panning until a general consensus of scFv variants was reached.  
 Eight ELISA plate wells (Costar) were coated with 50 uLs of 2 ug/mL anti-Myc 
(9E10 from BioXCell) monoclonal antibody, hCCLZ protein, or mLZ protein overnight at 
4°C. The library is first panned against anti-Myc antibody to ensure that only full length 
scFvs are screened for in subsequent rounds of panning. Panning was then performed on 
the hCCLZ and mLZ antigen to ensure the generation of cross reactive scFv sequences. 
Sequence diversity was monitored throughout all the steps by colony PCR and BstNI 
fingerprinting as well as Sanger Sequencing.  
 Monoclonal phage ELISAs were performed on unique clones with interesting 
complementary determining regions (CDRs). Single clone cultures (2 mL) grown up an 
OD600 of 0.5 in 2XYT media supplemented with 1% glucose and 100 ug/mL ampicillin. 
Single cultures were then induced with 1 mM IPTG and helper phage at a multiplicity of 
20 and were left shaking at 37°C for thirty minutes before switching to room temperature 
shaking. After three hours of shaking at room temperature, 50 ug/mL kanamycin was added 
to the cultures and they were left to shake overnight. ELISA plates were coated with 2 
ug/mL antigen (hCCLZ or mLZ) diluted in PBS overnight at 4°C. The next day the phage 
was harvested as described previously and used as a primary stain in an ELISA. Phage 
binding to the antigen was detected using a 1:2000 dilution of mouse anti-M13*HRP 




3.2.6 Protein expression and purification: antibodies  
Expression and purification of scAbs were performed by A. Qerqez (primarily) and 
A. C. Patterson-Orazem (for a few follow-up experiments). All IgG expression and 
purification were performed by A. Qerqez (Maynard Lab, U. T. Austin.) 
3.2.6.1 Single chain antibodies (scAbs)  
 To produce soluble scAbs (VL-linker-VH- human constant κ), the pMopac24 scFvs 
and pMopac54 vector were miniprepped and digested with SfiI (New England BioLabs) 
for 3 hours at 50°C. The inserts from the digest were then ligated into digested pMopac54 
vector, which includes the human constant κ sequence and a 12X his tag. The ligation was 
then electroporated into BL21 (DE3) competent cells (New England BioLabs) and plated 
on 2XYT agar plates supplemented with 100 ug/mL ampicillin and 1% glucose. Single 
colonies were sequence verified and inoculated into a 3 mL culture of TB supplemented 
with 100 ug/mL ampicillin and 1% glucose and were allowed to shake at 37°C until an 
OD600 of 5. Smaller cultures were then used to reinoculate a larger 250 mL culture of TB 
in 1 L flasks. Large cultures were supplemented with 1% glucose and 100 ug/mL ampicillin 
and were allowed to shake overnight at 37°C and 225 rpm. The next day the large cultures 
are harvested by centrifugation at 5000 rpm for ten minutes. The pellets are resuspended 
in fresh media and returned to flasks with fresh 250 mL TB supplemented with 100 ug/mL 
ampicillin. They were allowed to shake one hour at 25°C and were then induced with a 
final concentration of 1mM IPTG. They were allowed to shake for an additional five hours 
before the cells were harvested again. Osmotic shock was performed as previously 
described [71]. ScAbs were then purified using IMAC resin followed by size exclusion 
 
 34 
chromatography with a Superdex 75 column on FPLC (GE Healthcare). Protein 
concentrations were measured using Nanodrop 200 and purity was assessed by SDS-PAGE 
on a 4-20% gel (Bio-Rad).  
3.2.6.2 Immunoglobulin G (IgGs)  
 scFvs were generated into full length chimeric human IgG1 antibodies by cloning 
the VH and VL domains with primers into Igκ-Abvec and IgG-Abvec vectors as described 
previously [72]. IgGs were produced in CHO-K1 cells using 1:1 ratio of both heavy and 
light chain vectors and lipofectamine 2000 (Invitrogen). Transfection was performed 
following the manufacturer’s protocol using DMEM supplemented with 10% low IgG 
FBS.  Media was collected from T-150 transfections and replaced every two days over the 
course of an entire week. Media was then pooled and applied to a HiTrap protein A column 
(GE Healthcare) and eluted from the column using 0.1 M glycine (pH = 2.5). Purity of 
proteins was assessed by SDS-PAGE gels 4-20% (Bio-Rad) and concentration was 
measured using Nanodrop 2000.  
3.2.7 ELISA & Competition ELISA  
 ELISA and competition ELISA were performed by A. Qerqez (Maynard Lab at U. 
T. Austin). For all proteins, ELISA was performed by coating high binding plates (Corning 
9018) with 1 ug/mL mLZ, hCCLZ, or hCC overnight in PBS at 4°C. The following day 
plates were blocked with PBS supplemented with 5% milk and 0.1% Tween-20 (milk 
solution) for one hour at room temperature. ScAbs or IgGs were then serially diluted (1:5) 
in milk solution to the blocked plates. Secondaries were then added at 1:1000 dilution of 
either goat anti-human κ*HRP for scAbs or goat anti-human IgG Fc HRP for full length 
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antibodies. ELISAs were then developed using TMB solution (Thermo Scientific Pierce) 
and then quenched with 1 N HCl.  
 For competition ELISA, the scAbs (starting concentration of 50 ug/mL) were 
serially diluted in the presence of 1:1000-1:3000 dilution of scFv variant in the presence 
of milk solution. The phage mixture concentration remained constant across all wells. 
Competition of phage and scAbs was then detected using 1:2000 dilution of mouse anti 
M13 HRP antibody (Table 3.1, RRID: AB_673750) in milk solution. EC50s for 
competition were then calculated using GraphPad prism and compared to controls. 
Absorbance was measured using a plate reader at wavelength of 450nm.  
3.2.8 Dot Blots and Western Blots  
Dot and western blots were conducted by A. C. Patterson-Orazem and Y. Ku using 
protocols previously described in detail [35]. Briefly, protein samples were immobilized 
on methanol-activated polyvinylidene difluoride membranes (Millipore) by 
electrophoresis for Western blots and by direct deposition of 2 μL sample per dot for dot 
blots. Membranes were blocked overnight in 2% milk in PBS supplemented with 0.5% 
TWEEN-20, then probed with primary antibodies. Custom scAbs were tested at 1 µg/mL; 
IgGs were tested at 0.5 µg/mL to account for bivalency. Protein expression in cell lysates 
was confirmed using 1:1000 mouse anti-His (Table 3.1, RRID: AB_2533947). 
Commercial anti-LZ antibody (RRID: AB_2148649) was used as a positive control. 
Custom scAbs and IgGs were detected with 1:2000 (whole cell lysate dot blots) or 1:5000 
(all other experiments) dilution of HRP-conjugated goat anti-human κ light chain 
secondary antibody (RRID: AB_619883). Binding of control antibodies was detected using 
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1:2000 (whole cell lysate dot blots) or 1:5000 (all other experiments) dilution of HRP-
conjugated goat anti-mouse secondary (RRID: AB_2533947).  
Following application of primary and secondary antibodies, membranes were 
treated with HyGlo Quick Spray (Denville Scientific) and imaged using an Amersham 
Imager A600 (GE Healthcare). Western and dot blot results represent at least two 
biological replicates per antibody tested. Heat maps were generated by measuring the 
intensity of the 25-fold diluted cell lysate dots using ImageJ’s Gel Analyzer function [73]. 
Heat maps were generated in Origin 2016, and represent the average of four measurements 
across two biological replicates. 
3.2.9 Immunoprecipitation 
Immunoprecipitation was conducted by A. C Patterson-Orazem and Y. Ku. 
Antibodies in IgG format (0.5 ng/mL) were incubated with 10 mL spent hTM medium 
(experiment) or 10 mL buffer control (50 mM HEPES pH 7.5, 200 mM NaCl, 10% 
glycerol) overnight at 4 ᵒC on a rocker. Subsequently, PierceTM Protein A/G Plus agarose 
suspension (50 μL, ThermoFisher Scientific) was added, and samples were rocked an 
additional 2 hours at room temperature. Resin was pelleted by centrifugation (10 minutes 
at 1,000 x g), washed at least 5 times with 500uL buffer. Bound proteins were eluted by 
adding 50 μL 2x Laemmli buffer, incubated for 10 minutes at room temperature, followed 
by pelleting and removing the supernatant. Samples were supplemented to 3% v/v β-




3.2.10 Differential Scanning Fluorimetry  
Differential scanning fluorimetry was conducted by A. C. Patterson-Orazem. 
Melting temperatures were determined by differential scanning fluorimetry using 5x Sypro 
Orange (Invitrogen) and 1 μM IgG in 50 mM sodium phosphate pH 7.2, 150 mM NaCl 
(PBS). Samples, including protein-free controls to account for background fluorescence, 
were prepared on ice and dispensed into 96-well optical plates (Applied Biosystems) in 
triplicate, 30 μL per well. Thermal melts were performed from 25–95 °C with a 1 °C per 
min ramp rate using an Applied Biosciences Step-One Plus RT-PCR instrument with fixed 
excitation wavelength (480 nm) and ROX® emission filter (610 nm). Baseline-corrected 
data were analyzed via Boltzmann sigmoidal regression in Origin 2016; values represent 






3.2.11 Development and identification of candidate antibody sequences 
Development and identification of candidate antibody sequences was conducted by 
Ahlam Qerqez in the Maynard Lab at U. T. Austin; mouse immunizations were conducted 
by Jeong-min Hyun. Mice were immunized (Figure 3.2) with purified hCCLZ, a well-
characterized and stable N-terminal structural domain comprising residues 69-185 and 
including both dimer and tetramer regions [9]. While our intent was to raise additional 
antibodies against the mouse equivalent, mCCLZ (comprising residues 55-171), we later 
learned that cleavage by Factor Xa during purification resulted in a smaller immunogen 
mLZ (residues 93-171). Mice were given boosters alternating between hCCLZ and mLZ 
until sufficient immune response to both immunogens was observed in animal titers.  
Candidate DNA libraries were generated by extracting RNA from mouse spleens by PCR 
amplification of VL and VH using degenerate primers and subsequently cloning the light 
and heavy chains into scFv plasmid format. Library diversity was assessed by Sanger 
Sequencing of 10 individual colonies (~150 million single colonies for entire library). 
Truncated scFvs lacking C-terminal Myc tags were eliminated by panning against anti-
Myc antibodies, then myocilin-targeting antibodies were enriched in successive rounds of 
panning against hCCLZ and mLZ (Figure 3.2). Thirteen candidates were identified for 




Figure 3.2 Schematic workflow for mouse immunizations, phage display library 
construction and in-vitro selection of candidate antibody sequences. Mice were 
immunized then boosted with alternate rounds of hCCLZ and mLZ, then sacrificed. 
Antibody sequences extracted from their spleens with degenerate primers were 
cloned into a phage display library for successive panning against both immunogens. 




3.2.12 Initial evaluation of LZ-targeting scAbs  
Candidate scAbs were produced recombinantly in a soluble form in E. coli, 
expressed and purified for further characterization. All thirteen scAbs expressed well, but 
six exhibited poor hCCLZ binding in follow up ELISAs (data not shown) and thus were 
eliminated. The remaining 7 scAbs demonstrate a range of affinities towards purified 
hCCLZ and mLZ in ELISA (Figure 3.3 A), with strongest affinity and cross-reactivity 
observed for 1C7, 2F6, and 2G9. Competition ELISAs reveal that 1C7, 2F6, and 2G9 target 
the same epitope (Figure 3.3 B), whereas 1B9, 1G12, 1A1, and 2A4 appear unique.  
Next, 1C7, 2F6, 2G9, 1B9, 1G12, 1A1, and 2A4 scAbs were tested for their ability 
to recognize myocilin constructs in dot blot (Figure 3.3 C). I, this technique, the folded 
antigen is presented to the antibody, like in ELISA. For these experiments we tested 
recognition in the context of cell lysates, not purified proteins, but all were constructs we 
structurally characterized [9]. All antibodies preferentially target LZ (Figure 3.1 B), likely 
due to boosting with an aberrant mouse construct (see above). Interestingly, the majority 
of scAbs only weakly recognized the longer hNTD construct (residues 33-226), which 
includes additional linker regions before and after CCLZ, perhaps due to the previously 
noted conformational heterogeneity for hNTD [9]. ScAbs that initially displayed poor 
affinity to mLZ in ELISA (Figure 3.3 A) showed strong cross-reactivity to mLZ in dot blot, 
likely benefiting from the increased avidity afforded by the dimer-of-dimers architecture 





Figure 3.3 Testing of LZ-targeted scAbs. A. Binding affinity of candidate scAbs 
towards hCCLZ and mLZ, with scAbs important for later discussion highlighted with 
color and solid curves. B. Heat map representation of competition ELISA results 
wherein values ≥1 indicate competing epitopes. C. Heat map representation of scAb 
binding affinity in dot blots against cell lysates containing a range of N-terminal 
myocilin constructs or a control protein with identical tags. D. Representative dot 
blots testing scAb binding to heparin-enriched hTM-secreted myocilin. 
To confirm scAbs recognize full-length myocilin, dot blots with 2A4, 2G9, and 
1G12 next performed using immobilized myocilin from spent media of human TM cells 
(Figure 3D). Dot blots using 2A4 and 2G9 scAbs weakly, but reproducibly detected full-
length myocilin. This result was surprising for 2G9, which had exhibited the strongest 
affinity in ELISA but appeared to very weakly recognize full-length myocilin. Conversely, 
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dot blots with 1G12 elicited a strong signal for full-length myocilin, perhaps due to greater 
availability of its epitope within the protein sample or recognition of a less conformational 
epitope than 2A4 or 2G9 (see below).  
3.2.13 Evaluation of CC-targeting scAbs  
To identify antibodies targeting the CC domain (Figure 3.1 B), hCC (comprising 
residues 33-111) was panned against the scFv display library. Promising hits from phage 
display were expressed in E. coli as scAbs and analyzed as previously described for LZ-
targeting scAbs. These scAbs exhibit weak affinity for hCC and hCCLZ (Figure 3.4 A), as 
ELISA was conducted at concentrations up to 10 ug/mL (Figure 3.4 B) compared to 1 
ug/mL for LZ-scAbs; scAb 6F7 exhibited the strongest affinity. Competition ELISA 
revealed that all scAbs competed for the same epitope except for 7H4 (Figure 3.4 B).  
Epitope mapping of these new scAbs across the myocilin constructs in dot blot 
(Figure 3.4 C) demonstrates that 7C8 exhibits promising cross-reactivity towards mCCLZ, 
and 5D12 and 6C11 weakly recognize proteins within the negative control. Full-length 
myocilin from primary cell culture was recognized robustly by 5D12, 6C11, 6F7 and 7C8 
in dot blot (Figure 3.4 D). Of these, three were chosen for further characterization: 6F7 
(high affinity to CC without binding to negative controls), 7C8 (cross-reactivity to mouse 





Figure 3.4 Testing of CC-targeted scAbs. A. Binding affinity of candidate scAbs 
towards hCC and hCCLZ. B. Heat map representation of competition ELISA results 
wherein values ≥1 indicate competing epitopes. Squares marked with letters indicate 
antibodies which qualitatively compete (C) or don’t compete (NC) but for whom IC50 
could not be calculated. C. Heat map representation of scAb binding affinity in dot 
blots against cell lysates containing a range of N-terminal myocilin constructs or a 
control protein with identical tags. D. Representative dot blots testing scAb binding 
to heparin-enriched hTM-secreted myocilin. 
3.2.14 Conformational specificity of CC- and LZ-targeting IgGs  
 LZ-targeting (2A4, 2G9, 1G12) and CC-targeting (6F7, 7C8, 7H4) were converted 
next to IgG format. All but 2G9 were tested for thermal stability, with suitable a range of 
melting temperatures for constituent Fab domains from 64-77 °C [74]. All six IgGs 
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recognize the same epitopes as identified in scAb format but displayed apparent increased 
affinity, as expected for the bivalent format. Since 7H4 still bound the negative control 
samples, and 7C8 exhibited very weak affinity, neither was considered further.  
Conformational specificity was assessed by comparing results from dot blots 
(Figure 3.5 A) and Western blots (Figure 3.5 B), experiments conducted in parallel with 
specific quantities of purified myocilin constructs. Most IgGs displayed robust affinity 
towards hCCLZ and hNTD in dot blots, detecting as little as 5ng. In Western blot, where 
the samples are denatured, detection was weak (1G12), very weak (6F7) or not visible 
(2A4). 2G9 robustly recognized only hCCLZ in both Western blot and dot blot, from which 
we deduce that its epitope includes the C-terminal disulfide bond composed of two Cys185; 
this epitope is obstructed in longer constructs such as hNTD and full-length myocilin. Thus, 
at this point 2G9 was removed from further consideration. Weak binding of 6F7 to hNTD, 
but not to hCCLZ, in Western blot suggests a partial linear epitope including further N-
terminal residues not present within hCCLZ. 
Finally, LZ-targeting (2A4, 1G12) and CC-targeting (6F7) IgGs were tested for 
their ability to purify endogenous myocilin from spent media of human TM cells. All three 
immunoprecipitated full-length myocilin, as well as trace amounts of an N-terminal (~25 
kDa) fragment for 2A4 and 1G12 (Figure 3.5 B). Qualitatively, 1G12 immunoprecipitated 
more myocilin than did 2A4 despite similar epitope and affinity. This observation is 
consistent with the finding that 2A4 is selective for a folded conformation whereas 1G12 
recognizes a less structural epitope, allowing it to bind additional conformers of myocilin 




Figure 3.5 Testing of IgG targeting CC and LZ. To assess conformational specificity, 
IgG binding was assessed in A. dot blot and B. western blot against nanogram 
quantities of purified myocilin. C. IgG immunoprecipitation of hTM myocilin from 
spent media reveals a ~55kDa band corresponding to full-length myocilin, detected in 




3.3 DISCUSSION  
The use of conformationally-selective antibodies has been invaluable in gaining 
new insight into misfolding disease like Alzheimer’s [75] and Parkinson’s [76]; 
conversely, not critically evaluating antibodies in use hinders research, as noted for 
Parkinson’s over a decade ago [77]. Structure-based conformational antibodies are even 
now under development to treat protein misfolding diseases including Alzheimer’s 
(amyloid-beta [59]), amyloidosis (transthyretin [78]) and amyotrophic lateral sclerosis 
(superoxide dismutase 1 [79, 80]). Inspired by the advances made for other misfolding 
diseases by the availability of new antibody reagents, we set out to identify conformational 
antibodies that could be used to provide new structural context for the misfolding-prone 
myocilin protein in eye research, with the long-term goal of as conversion to a diagnostic 
or therapeutic. Our antibodies conform to the movement towards sequence-based 
recombinant antibodies [3, 6], which offer superior reproducibility and longevity over 
traditional monoclonal and polyclonal antibodies.  
We identified 6F7, which targets human CC, as well as 2A4 and 1G12, which detect 
LZ. 6F7 and 2A4 are highly sensitive to the conformation of myocilin, as they only 
recognize the protein when in the folded form and not when it is denatured. 2A4 and 1G12 
are both cross reactive with mouse LZ, streamlining research reagents across relevant cells, 
tissue samples, and glaucoma animal models [81, 82]. It is likely that a conformational 
epitope conserved in mouse and human is conserved across other species used in glaucoma 
research, such as monkey or cat, as has been found for Ebola virus nucleoprotein [83] and 
pollen antigens [84]. 
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Through our workflow of antibody development, we have already started to glean 
new insight about myocilin present in spent media from human TM cells. First, our finding 
that the LZ-targeting IgGs 2A4 and 1G12 exhibit similar affinity towards recombinant 
myocilin yet the less-conformational 1G12 immunoprecipitates more myocilin from TM 
media than 2A4 indicates there is a heterogenous mixture of myocilin, including both 
native and non-native conformations. While the N-terminal region confers the 
oligomerization state of myocilin  [9, 85], endogenous myocilin has been identified in a 
variety of oligomerization states, ranging from dimer [86] to tetramer and higher [38, 39], 
with unknown functional or glaucoma relevance. Our antibodies offer the first opportunity 
to compare these myocilin species, and see how they change with glaucoma-relevant 
stressors, including but not limited to myocilin mutations [62], steroid treatment [51], 
mechanical stress [64] and oxidative stress [87, 88]. Second, immunoprecipitation with our 
new IgGs yielded full-length myocilin (~55kDa) as well as a minority of truncated 
myocilin (~25kDa). While myocilin cleavage has been observed in mammalian expression 
systems [40, 67], to our knowledge, ours is the first observation of myocilin fragments in 
spent media from primary cell culture; fragments may have been detected in lysed TM cells 
[34]. Proteolytic cleavage for myocilin may play a functional role, as it does for 
olfactomedin family-members gliomedin [42, 43] and latrophilin [41]. More broadly, the 
availability of a myocilin epitope for detection by any given antibody might be modulated 
by posttranslational modification [29, 39] and contextual binding partners. In sum, we 
anticipate that these new antibodies, in conjunction with existing antibodies targeting linear 
epitopes and those detecting other structural domains, will allow researchers to map 
myocilin with a new level of detail, in many relevant samples across vision research.  
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CHAPTER 4. DIFFERENTIAL MISFOLDING PROPERTIES OF 
GLAUCOMA-ASSOCIATED OLFACTOMEDIN DOMAINS 
FROM HUMAN AND MOUSE. 
Adapted from “A. C. Patterson-Orazem, S. E. Hill, Y. Wang, I. M. Dominic, C. K. Hall & 
R. L. Lieberman; Differential misfolding properties of glaucoma-associated olfactomedin 
domains from human and mouse; in press ACS Biochemistry, 2019.” Reproduced with 
permission from ACS Biochemistry; unpublished work copyright 2019, American 
Chemical Society. 
 
I contributed structural determination of mouse OLF, ThT-binding experiments, in-vitro 
aggregation kinetics experiments and some thermal stability measurements, and the design 
and execution of all figures which include these data. I contributed to the organization, 
writing and editing of the manuscript. 
 
S. E. Hill contributed to experimental design, initial expression and purification of mouse 
OLF, interpretation of aggregation kinetics, and atomic force microscopy experiments and 
figure. Y. Wang contributed molecular dynamics simulations and related sub-figures. I. M. 
Dominic contributed protein purifications and thermal stability measurements. C. K. Hall 
contributed molecular dynamics experimental design and editing of the paper. R. L. 
Lieberman contributed to experimental design and to the writing of the manuscript.  
4.1 Abstract.  
Mutations in myocilin, predominantly within its olfactomedin (OLF) domain, are 
causative for the heritable form of open angle glaucoma in humans. Surprisingly, mice 
expressing Tyr423His mutant myocilin, corresponding to a severe glaucoma-causing 
mutation (Tyr437His) in human subjects, exhibit a weak, if any, glaucoma phenotype. To 
address possible protein-level discrepancies between mouse and human OLFs, which 
might lead to this outcome, biophysical properties of mouse OLF were characterized for 
comparison with those of human OLF. The 1.55 Å resolution crystal structure of mouse 
myocilin OLF reveals an asymmetric 5-bladed β-propeller that is nearly indistinguishable 
from previous structures of human OLF. Wild type and selected mutant mouse OLFs 
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mirror thermal stabilities of their human OLF counterparts, including characteristic 
stabilization in the presence of calcium. Mouse OLF forms thioflavin T-positive aggregates 
with similar end-point morphology as human OLF, but amyloid aggregation kinetic rates 
of mouse OLF are faster than human OLF. Simulations and experiments support the 
interpretation that kinetics of mouse OLF are faster because of decreased charge repulsion 
arising from more neutral surface electrostatics. Taken together, phenotypic differences 
observed in mouse and human studies of mutant myocilin could be a function of 
aggregation kinetics rates, which would alter the lifetime of putatively protofibrillar 
intermediates.    
4.2 Introduction.  
Mouse models offer valuable insights into human disease progression and are often 
the first testing grounds for novel treatments. In the case of protein misfolding disorders, 
however, mouse models have been somewhat less successful, either failing to replicate key 
disease phenotypes found in humans or exhibiting a weaker phenotype. In mouse models 
of tau-based Alzheimer disease and transthyretin-based amyloidosis [89, 90], differences 
between the mouse and human proteins have been attributed to differences in observed 
phenotypes. At the molecular level, it is known that even minor changes in protein 
sequence can have dramatic effects on protein structure, stability, and misfolding properties 
in the cell [91].  
A recent addition to the list of protein misfolding disorders is a heritable sub-type 
of the age-onset ocular disease glaucoma, a worldwide leading cause of blindness. 
Mutations in human (Homo sapiens) myocilin (Uniprot Q99972), predominantly within its 
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olfactomedin (HsOLF) domain, are causative for glaucoma in approximately 3 million of 
the 70 million total glaucoma patients [92, 93]. The predominant pathogenic mechanism is 
a toxic gain of function: mutant myocilin is prone to cytotoxic aggregation within the 
trabecular meshwork (TM) cells that maintain the extracellular matrix that serves as an 
anatomical sieve to drain aqueous humor. This cytotoxicity hastens the causal risk factor 
of elevated pressure leading to retinal ganglion cell (RGC) death and vision loss 
characteristic of glaucoma [94]. Typically, individuals expressing a mutant form of 
myocilin, such as the variant Tyr437His, exhibit severely elevated intraocular pressure 
(IOP, 44 mmHg vs 20 mmHg in control population) at a young age (20 years old) [95, 96]. 
Data to date indicate that myocilin is not otherwise a susceptibility gene for sporadic forms 
of glaucoma [22]. 
Numerous glaucoma rodent models are available and widely used in the field [82], 
but for myocilin-associated glaucoma, a robust IOP elevation phenotype accompanied by 
RGC loss has been a challenge to elicit in mouse. In two mouse models that express either 
the human Tyr437His myocilin mutation [97] or its equivalent in Mus musculus myocilin 
(Uniprot O70624), Tyr423His [98], modest IOP elevation was measured [97, 98], but only 
in older mice. In these models, which both used the bacterial artificial chromosome method 
that overexpresses the target protein, IOP elevation was accompanied by some 
degenerative features in RGCs [97, 98]. No increase in IOP was observed in mice when 
Tyr423His was introduced in the endogenous mouse myocilin gene [99]. In a fourth 
transgenic model, high levels of human mutant myocilin Tyr437His expressed specifically 
in eye drainage structures and sclera using cytomegalovirus methods, exhibit the strongest 
and earliest glaucoma-like phenotypes to date [18].  
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Here we test the hypothesis that molecular level differences in HsOLF and mouse 
OLF (MmOLF) explain the differing phenotypes observed in these myocilin-glaucoma 
models. Although HsOLF and MmOLF share high sequence identity (87%), differences 
are observed in regions thought to template amyloid aggregation [36], raising the 
possibility this could contribute to species-based differences in disease phenotype, as in 
other misfolding disorders. We compare structural, biophysical, and aggregation properties 
of MmOLF with well-studied characteristics of HsOLF. Our results demonstrate high 
levels of similarities between the two proteins in their folded state and final aggregated 
states, but faster aggregation rates observed for MmOLF point to the possibility that a toxic 
species relevant to glaucoma is hidden in a transiently present protofibrillar intermediate.  
4.3 Materials and Methods. 
4.3.1 Molecular biology.  
Molecular biology was conducted by A. C. Patterson-Orazem and I. M. Dominic. 
Codon-optimized MmOLF was synthesized and sub-cloned by Genscript into pMAL-c4x 
vector similar to previously published HsOLF, except that the Factor Xa cleavage site was 
replaced with a tobacco etch virus (TEV) protease cleavage site[100]. Maltose binding 
protein (MBP)-MmOLF fusion variants Ala413Thr, Asp366Ala, Tyr423His and 
Ile485Phe, and MBP-HsOLF variant Ile431Val Thr435Ile were all produced by site-
directed mutagenesis following manufacturer’s recommended protocol (Quick-Change 
Lightening II Kit, Agilent) and verified by DNA sequencing (Operon or Genscript). Primer 
sequences are provided in Table 4.1. 
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Table 4.1 Primers used for site-directed mutagenesis of MmOLF and HsOLF used in 
this manuscript. 


























4.3.2 Expression and purification.  
HsOLF and MsOLF expression and purification, as previously described [55], were 
conducted by A. C. Patterson and I. M. Dominic. E. coli Rosetta Gami 2 cells transformed 
with myocilin plasmid were inoculated to OD600 ~ 0.1 and grown in Superior Broth (US 
Biological) at 37 °C to OD600 of 0.8 to 1.0, cooled to 18 °C, then induced with 0.5 mM 
isopropyl-β-D-thiogalactopyranoside and 1 mM CaCl2 overnight. Cells were harvested by 
centrifugation, flash cooled in liquid nitrogen, and stored at -80 °C. Cell paste (5 g) was 
gently suspended in 20 mL chilled phosphate buffered saline composed of 10 mM 
Na2HPO4/KH2PO4, 200 mM NaCl (PBS), supplemented with half an EDTA-free Roche 
Protease Inhibitor tablet and 1 mM EDTA, lysed by French press (Sim-Aminco French 
Press, 25 mL FA-023 cell from Thermo Electron Corporation) and centrifuged at 
110,000xg (Beckman Avanti JXN3, JS-24.15 rotor). Clarified cell lysate was purified on 
AKTA Pure and Purifier systems (GE Healthcare) by amylose affinity chromatography (25 
mL column packed with New England BioLabs Amylose Resin), equilibrated with PBS, 
eluted with PBS supplemented with 10 mM maltose, and concentrated in 15 mL 30 kDa-
cutoff Amicon filters (Millipore) prior to fractionation by size-exclusion chromatography 
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(SEC) with a Superdex-75 pg (GE Healthcare) in PBS buffer. For Tyr423His and 
Ile485Phe MBP-MmOLF variants, fractions proximal to 55 mL elution volume were 
concentrated and further purified using a Superdex-75 GL (GE Healthcare) to eliminate 
residual aggregated protein. Fractions containing monomeric MBP-OLF fusion proteins 
were cleaved by TEV protease [101] using a 1 TEV:5 MBP-OLF mass ratio overnight at 
room temperature, then purified by nickel affinity (1mL HisTrap FF, GE Healthcare), 
amylose affinity and SEC as previously described [55]. After cleavage, pure protein was 
concentrated with 15-mL 10 kDa-cutoff Amicon filtration units (Millipore).  
For aggregation kinetics assays, cleaved MmOLF was subjected to cation-exchange 
after the first amylose step to bind and remove trace TEV protease. This was accomplished 
by diluting OLF-containing fractions to 50mM NaCl with 10 mM Na2HPO4/KH2PO4 and 
applying the sample to a HiTrap CaptoS column (1mL, GE Healthcare) equilibrated with 
10 mM Na2HPO4/KH2PO4, 50 mM NaCl. Residual TEV protease was eluted from the 
column with gradient to 2M NaCl.  
Protein purity was assessed by standard SDS-PAGE analysis with Coomassie 
staining. Protein concentrations were determined by spectrophotometry using molar 
extinction coefficients for fusion proteins (human: 134,775 M-1cm-1, mouse: 133,285 M-
1cm-1) or for cleaved OLF (human: 68,425 M-1 cm-1 and mouse: 65,440 M-1cm-1) calculated 




4.3.3 Crystallization and structure determination.  
Crystallization and structure determination were conducted by A. C. Patterson-
Orazem with data collection assistance from S. E. Hill. Rectangular prismatic crystals of 
MmOLF, 50-70 μM in diameter, grew within 3 weeks at 16 °C in 4 µL sitting drops 
containing 1:1 (v/v) of 30 mg/mL MmOLF in PBS pH 7.2 and mother liquor solution 
containing 10% PEG-8000, 200 mM MgCl2. Diffraction data were collected at the 
Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline and 
processed using HKL-3000 [103]. The MmOLF structure was solved by molecular 
replacement in Phaser [104] using the HsOLF structure 4WXQ as a search model. The 
MmOLF model was iteratively built and refined using Coot [105] and Phenix.refine [104]. 
The structure has been deposited to the PDB with ID: 6NAX, and statistics are shown in 
Table 4.2. Figures were prepared in PyMOL [106], and electrostatics using APBS-




Table 4.2. Data collection and refinement statistics for the structure of the 
olfactomedin (OLF) domain of mouse myocilin, PDB 6NAX. 
Data Collection 
Space group P4 
Cell dimensions 
a, b, c (Å) 
α, β, γ (degrees) 
 
112.0, 112.0, 44.1  
90, 90, 90 







Redundancy 4.5 (3.9) 
Completeness (%) 98.5 (95.2) 
Wilson B-factor 11.6 
Rsym 0.0671 (0.210) 
I/Iσ 18.0 (6.1) 
CC1/2 0.996 (0.950) 
CC* 0.999 (0.987) 
Refinement 
Resolution (Å) 33.11  - 1.55 (1.61  - 1.55) 
Reflections  
Used in refinement 




R-work/R-free 0.158 (0.173) / 0.178 (0.201) 



































4.3.4 Thermal stability assay.  
Thermal stability was measured by differential scanning fluorimetry using Sypro 
Orange (Invitrogen), as previously described [55], and conducted by A. C. Patterson-
Orazem and I. M. Dominic. Final mixtures of 30 μL were prepared at room temperature in 
96-well optical plates (Applied Biosystems) and contained protein solutions at a final 
concentration of 0.5–1.5 μM in HEPES-buffered saline (10 mM HEPES pH 7.5, 200 mM 
NaCl). Where indicated, 50 mM maltose and 10 mM CaCl2 were present. Each experiment 
contained control wells accounting for background protein, maltose and calcium 
fluorescence. Fluorescence data were collected on an Applied Biosciences Step-One Plus 
RT-PCR instrument equipped with fixed excitation wavelength (480 nm) and ROX® 
emission filter (610 nm). Thermal melts were performed from 25–95 °C with a 1 °C per 
min increase and acquired data were analyzed with Igor Pro, version 6.37 (WaveMetrics). 
4.3.5 Thioflavin-T (ThT) endpoint fluorescence and de novo aggregation assays.  
Endpoint fluorescence and de novo aggregation assays were conducted by A. C. 
Patterson-Orazem, with assistance from S. E. Hill. Aggregated MBP-MmOLF species 
fractionated by Superdex-75 pg were concentrated to 30 μM protein and supplemented 
with 10 μM ThT in PBS. Aliquots (40 μL) were dispensed in triplicate in half-area flat-
bottomed 96-well non-binding plates (Corning #3993). After incubation for 10 min, ThT 
fluorescence was measured at room temperature using excitation filter 440/30 nm and 
emission filter 485/20 nm (BioTek Synergy 2). Results represent the average of two 
biological replicates.  
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For de novo aggregation assays, triplicate samples comprising 150 μL of 30 μM 
cleaved, monomeric MmOLF and 10 uM ThT in PBS were incubated at 42 °C in black flat-
bottom medium binding plates (Greiner Bio One #655076), Fluorescence was monitored 
over 72 hours at 10-minute intervals using the same BioTek plate reader and filters as listed 
above [100]. Representative results were normalized to the maximum fluorescence of wild 
type HsOLF and plotted in Origin Professional 2016. 
4.3.6 Coarse grain (PRIME20) molecular dynamics simulations.  
Molecular dynamics simulations were conducted Y. Wang under direction of C. K. 
Hall. Discontinuous molecular dynamics (DMD) [108], a fast alternative to conventional 
molecular dynamics, were used in conjunction with the PRIME20, coarse-grained protein 
model developed in the Hall group [109] to simulate aggregation of MmOLF derived 
peptides, analogous to those of human peptides [110]. In the PRIME20 model, each of 
twenty different amino acids has three backbone spheres (NH, Cα and CO) and one 
sidechain sphere (R). Glycine does not have a sidechain sphere. Each sidechain sphere of 
the twenty different amino acids has a distinct hard sphere diameter (effective van der 
Waals radius) and distinct sidechain-to-backbone distances (R-Cα, R-NH, R-CO). The two 
major types of non-bonded interactions captured in PRIME20 are directional hydrogen 
bonding between backbone NH and CO spheres modeled as a directional square well 
potential and sidechain-sidechain square well interactions between any pair of the twenty 
different amino acids. Cheon et al. [111] used a perceptron learning algorithm to reduce 
the 210 possible independent square well depths between the 20 different amino acids to 
19 different parameter groups while maintaining the 210 independent square well widths 
to ensure physically meaningful pair interaction energies in discriminating decoys from 
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native structures in the PDB database. All the other non-bonded interactions are modeled 
as hard sphere interactions. A detailed description of the derivation of the geometric and 
energetic parameters of the PRIME20 model is given in earlier work [109, 111, 112]. 
DMD/PRIME20 simulations of mouse P1 and P3 peptide aggregation were 
performed in the canonical ensemble (fixed number of particles, constant volume and 
temperature). The simulation temperature was maintained constant by using the Andersen 
thermostat [113]. The system contained eight monomeric peptides in a cubic box with box 
length equal to 110.0 Å corresponding to a total peptide concentration of 20 mM. The 
reduced temperature was defined as T*= kBT/εHB, where the hydrogen bonding energy, 
εHB=12.47 kJ/mol. The reduced temperature T
* was chosen to be 0.2, which corresponds 
to 342 K in real temperature [114]. Ten independent simulation runs were performed, each 
lasting for at least 220 μs. 
The aggregation propensities of human and the mouse P3 were calculated by 











where 𝑛𝐻𝐵(𝑖) is the total number of backbone hydrogen bonding sites (NH and 
C=O beads) on the 𝑖𝑡ℎ peptide in the aggregate that form β-sheet hydrogen bonds, and 
𝑛𝑆𝑖𝑡𝑒(𝑖) is the total number of NH and C=O beads on the 𝑖
𝑡ℎ peptide in the aggregate. N is 
the total number of peptides in the system. β ranges from 1 for a perfect β-sheet structure 
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with strong amyloid forming propensity, to 0 for a monomeric state or disordered oligomer 
with weak amyloid forming propensity. 
4.3.7 Atomic force microscopy (AFM). 
Atomic force microscopy was conducted by S. E. Hill. Immediately after the ThT 
aggregation assay above, triplicate samples comprising 150 L each were removed, 
combined into a 1.5 mL centrifuge tube, and left at room temperature overnight to pellet 
by gravity. After visible separation of the insoluble aggregates into a pellet, 40 L of the 
pellet sample was deposited onto freshly-cleaved mica for 30 minutes, rinsed for 3 seconds 
with ultrapure water, and left to dry overnight in a Petri dish. After drying, the samples 
were imaged in air with a MFP-3D atomic force microscope (Asylum Research) using 
PPP-FMR (NanoAndMore) silicon tips with nominal tip radii less than 7 nm. The 
cantilever was driven at 60–80 kHz in alternating current mode and a scan rate of 0.5 Hz 
with 512 x 512-pixel or 1024 x 1024-pixel resolution. Raw image data were corrected for 




4.4 RESULTS  
4.4.1 MmOLF structure.  
To gain insight into the structural similarities and differences between native 
MmOLF and HsOLF, we solved the crystal structure of MmOLF, to 1.55 Å resolution 
(Table 4.2). The 5-bladed β-propeller is nearly identical to that of HsOLF (root meant 
squared deviation (RMSD) = 0.7 Å, Figure 4.1 A). The disulfide clasp that covalently links 
the N and C termini is conserved, the heptacoordinate Ca2+, pentacoordinate Na+ and 
corresponding coordinating ligands identified for HsOLF [8] are all present and in similar 
conformations (Figure 4.1 B). However, while the surface electrostatics of HsOLF are 
predominantly negative [8], the MmOLF surface is more varied, with distinct positively-




Figure 4.1 MmOLF and HsOLF share key structural features. (A) Superposition of 
MmOLF structure (dark red, 1.55 Å resolution) and HsOLF (PDB code 4WXQ, gold, 
2.15 Å resolution), view of top face, RMSD = 0.73 Å. (B) Ca2+, Na+, and corresponding 
coordinating residues in the central cavity of MmOLF and HsOLF are nearly 
identical. Waters are shown as red spheres, and hydrogen bonding interactions < 3Å 
are shown as dashed lines. (C) Surface electrostatics demonstrate similar potentials 
across the top face, but increased positive charge on the bottom face of MmOLF 
relative to HsOLF. Surface potentials are colored negative (red, −5 kT/e-) to positive 




Glaucoma-associated HsOLF mutations selected next as representatives for further 
inspection and study in the context of MmOLF represent a range of residual thermal 
stability [12, 55] and disease phenotypes [115]. These variants range from Ala427Thr, 
associated with variable (familial and sporadic, and diagnosed past the age of 65) glaucoma 
phenotypes in a small population [116] and which might only be causative in presence of 
other genetic risk factors, to the severe Tyr437His mutation which results in juvenile-onset 
glaucoma symptoms and dramatic elevation in IOP [96] (Figure 4.2 A). Tyr437His and 
Ile499Phe are located within the hydrophobic interface between propeller blades, while 
Ala427Thr and Asp380Ala are proximal to the calcium-binding site (Figure 4.2 A).  
 
Figure 4.2 Biochemical environment of glaucoma-causing myocilin mutations. (A) 
Representing a range of clinical phenotypes (table to the right)[115], select myocilin 
mutations are either in a hydrophobic interface between the blades, highlighted by 
triangles, or near the calcium-binding site, indicated by shaded circle. (B-E) Overlay 
of mouse, dark red, and human, gold, OLF structures demonstrate similarities in the 
biochemical environment of (B) human Tyr437 and its mouse equivalent Tyr423; (C) 
Ala427 and mouse Ala413; (D) Asp380 and mouse Asp366; and (E) Ile499 and mouse 
Ile485. Waters are shown as red spheres, and hydrogen bonding interactions < 3Å are 




Inspection of these positions in the context of MmOLF reinforces the similarity 
between the HsOLF and MmOLF structures. Tyr423 in MmOLF (due to a shorter N-
terminal signal peptide in MmOLF numbering is offset from HsOLF by 14 amino acids) 
participates in hydrophobic packing and water-mediated beta-turn stabilizing hydrogen 
bonding interactions (Figure 4.2 B), both of which are expected to be strongly impacted by 
mutation to histidine. Ala413 in MmOLF is located under surface loops known to be mobile 
in HsOLF [8] and other OLF domain family members [117], and should be able to 
accommodate conservative mutations (Figure 4.2 C). Mutation of Asp366 abolishes 
calcium binding (Figure 4.2 D) by removing a key metal-coordinating side chain [8, 118]. 
Ile485 is engaged in hydrophobic packing, which is likely disrupted by the increased steric 
hindrance of mutation to phenylalanine (Figure 4.2 E). Thus, based on structure, these 
mutations to MmOLF are expected to have a similar impact on stability and aggregation as 
previously observed for HsOLF.  
4.4.2 Thermal stability of wild-type and mutant MmOLFs.  
Expression and purification of MmOLFs proceeded as for HsOLF published 
previously[55], utilizing a N-terminal maltose binding protein (MBP) fusion to enhance 
folding efficiency and as a purification handle. Similar to purification of HsOLF, the initial 
MBP-MmOLF fusion protein is isolated from E. coli in two forms (Figure 4.3 A): a 
misfolded, thioflavin-T-positive aggregate suggestive of amyloid (Figure 4.3 B,C) and a 
properly folded form used subsequently for characterization, including the structural 
analysis above, thermal stability and aggregation kinetics assays below. Thermal stability 
of wild-type MmOLF resembles that of HsOLF (Table 4.3). All four aforementioned 
disease variants, Ala413Thr, Ile485Phe, Asp366Ala, and Tyr423His, result in 
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compromised MmOLF stability, with similar trends to HsOLF variants [55], albeit with 
slightly higher melting temperatures (Table 4.3, Figure 4.4). Wild-type MmOLF as well as 
MmOLF variants Ala413Thr, Ile485Phe, and Tyr423His, were stabilized in the presence 
of calcium, confirming that a calcium binding site is retained, as in HsOLF [8, 118]. The 
outlier is the MmOLF Asp366Ala variant (Table 4.3), confirming the critical importance 
of Asp366 to calcium binding in MmOLF, like its equivalent Asp380 in HsOLF [118] and 




Figure 4.3 Aggregates of MBP-MmOLF isolated from E. coli are ThT-positive, a 
hallmark of amyloid. (A) Aligned chromatograms from Superdex-75 purifications of 
wild-type and mutant MBP-MmOLF fusion proteins. (B) ThT fluorescence of MBP-
MmOLF aggregates compared to selected monomeric MBP-OLFs and (C) 
corresponding SDS-PAGE analysis demonstrates that, for equal amounts of protein, 




Table 4.3. Thermal stability of wild-type and mutant MmOLF resemble HsOLF 







Figure 4.4 Representative differential scanning fluorimetry thermal melt curves for 
(A) MmOLF wild-type and mutants and (B) HsOLF wild-type and mutant, with and 










Wild Type 52.3 ± 0.1 + 7.8 53.0 ± 0.5 + 6.6 
A413T (A427Ta)b 50.8 ± 0.1 + 8.1 48.3 ± 0.3 + 6.9 
D366A (D380A)b 47.5 ± 0.2 − 1.2 46.6 ± 0.3 − 1.5 
I485F (I499F)b 43.9 ± 0.5 + 8.5 42.8 ± 0.1 + 7.6 
Y423H (Y437H)b 42.1 ± 0.1 + 9.8 40.3 ± 0.4 + 8.3 
(I431V/T435I)c n/a n/a 54 ± 2 +8.8 
aNumbering for HsOLF mutants shown in parentheses. 
bLiterature values [118]  listed.  
cValues obtained using cleaved HsOLF. 
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4.4.3 Aggregation properties of MmOLF. 
 Given the result of ThT-positive cellular aggregates produced by E. coli 
during expression, coupled with nearly identical thermal stabilities and native structures of 
MmOLF and HsOLF, similar in-vitro aggregation kinetics were expected. Surprisingly, 
MmOLF forms ThT-positive aggregates faster than HsOLF under assay conditions 
developed previously for HsOLF, namely aggregation at 42 °C without agitation in a 
fluorescence plate reader [36] (Figure 4.5 A), with statistically significant differences in 
ThT fluorescence (p < 0.0001, ANOVA) at 24 and 72 hour timepoints.  
 One possible explanation for the increased initial rate of MmOLF 
aggregation includes differences in the MmOLF sequence within previously-identified 
HsOLF amyloidogenic peptide regions [36]. These amyloidogenic stretches (Figure 4.5 B) 
comprise HsOLF residues 326−337 (P1, MmOLF residues 312−323) and residues 426−442 
(P3, MmOLF residues 412−428). Peptides P1 and P3 replicate disparate fibril 
morphologies associated with different aggregation conditions for the full HsOLF domain 
[36]. For the experimental conditions used here, which provide high throughput in-situ ThT 
kinetic data (Figure 4.5 A, and experimental section), aggregation is thought to be 
promoted by P3. We previously validated the end point aggregate formed in this non-
nucleation dependent growth process as amyloid by using Congo Red absorbance, Fourier 




Figure 4.5 MmOLF aggregation kinetics, and DMD/PRIME20 simulations of 
amyloidogenic mouse P3. (A) Aggregation of purified MmOLF, HsOLF and HsOLF 
variant I431V/T435I monitored by ThT fluorescence at 42 °C over 72 hours; * (p < 
0.01) and *** (p < 0.0001) represent statistically significant differences relative to 
HsOLF at 24h and 72h.  (B) Location of amyloidogenic stretches P1 and P3 within 
the OLF domain (left), and sequence alignment of mouse and human P1 and P3 
(right). (C) Simulated L-shaped mouse P3 protofilament in schematic representation 
(above) with hydrophobic and polar residues indicated in white and green, 
respectively, and representative final simulation snapshot (below). (D) Simulated U-
shaped conformation of human P3 protofilament in schematic representation (above) 
and representative final simulation snapshot (below). (E) Average number of 
interpeptide backbone hydrogen bonds (H-bonds) formed per residue and (F) 
average β-sheet propensities calculated for human and mouse P3 peptides. All error 




To test whether differences in aggregation propensity between HsOLF and MmOLF 
might originate in sequence differences in respective P1 (Ala to Ser) or P3 (Ile to Val, Thr 
to Leu) regions (Figure 4.5 B), we first turned to coarse grain molecular modeling using 
DMD/PRIME20, a method we used recently to simulate aggregation of P1 and P3 peptides 
derived from HsOLF [110]. For P1, no obvious differences were identified between mouse 
and human P1 aggregation simulations (Figure 4.6, Figure 4.7), consistent with the single 
conservative substitution. By contrast, mouse P3 peptides, initially in random coil 
configurations, aggregate to form a parallel, in-register protofilament with a predominantly 
L-shaped backbone conformation in eight out of ten runs (Figure 4.5 C, Figure 4.8), a 
different shape and a more homogeneous aggregate compared to human P3, which formed 
a U-shaped backbone conformation in just two out of ten runs (Figure 4.5 D) [110].  Based 
on the average number of inter-peptide hydrogen bonds formed per residue calculated over 
the last third of the simulation trajectories (Figure 4.5 E), the two different residues, Val417 
and Ile421 (corresponding to human residues Ile431 and Thr435), result in higher average 
β-sheet-forming propensity in the C-terminal region of the peptide and less variability than 
for human P3. The average β values or amyloid forming propensities for the entire peptide 
sequence are β(mouse P3) = 0.52±0.05, and β(human P3) = 0.43±0.19, suggesting that 
mouse P3 has a stronger amyloid forming propensity than human P3 (Figure 4.5 F). These 
differences do not reach statistical significance (p < 0.0985 by normal distribution test), 
likely due to the heterogeneous conformational landscape of simulated human P3 
aggregates, but in principle suggest variations in P3 may explain experimental differences 




Figure 4.6 Representative simulation results, schematic representations, and analysis 
of the dominant morphologies of human P1 and mouse P1 aggregates. (A) human P1 
(B) mouse P1. Green amino acids are hydrophilic. (C) Average number of 
interpeptide backbone hydrogen bonds (H-bonds) formed per residue, numbered 
according HsOLF, and (D) average β-sheet propensities calculated for human and 
mouse P1 peptides. 
 
Figure 4.7 Simulation snapshots (A-J) of mouse P1 aggregates from ten independent 
DMD simulations after 220 μs. 
 
Figure 4.8 Simulation snapshots (A-J) of mouse P1 aggregates from ten independent 




To experimentally evaluate whether the two amino acid differences in mouse P3 
sequence account for more facile MmOLF aggregation, the double HsOLF variant 
Ile431Val/Thr435Ile was generated and subjected to an aggregation assay, in parallel with 
wild type HsOLF and MmOLF (Figure 4.5 A). Surprisingly, aggregation kinetics were 
more similar to HsOLF than to MmOLF, indicating that the specific residues in the mouse 
P3 sequence are not sufficient to increase MmOLF aggregation rates or increase ThT 
binding of the end-point aggregate. Differences between HsOLF wild type and the 
Ile431Val/Thr435Ile variant were not statistically significant at 24 hours (p = 0.1645), 
though they were at 72 hours (p = 0.0074, ANOVA).  From this study, we infer that other 
sequence differences, scattered throughout the rest of the MmOLF domain, facilitate 
changes in the aggregation properties relative to HsOLF. 
4.4.4 End-point aggregate morphologies of MmOLF and HsOLF.  
Although sequence differences in P3 do not fully explain differing aggregation 
kinetics of HsOLF and MmOLF, cgMD results suggest structural differences in the 
aggregate at the molecular level.  To determine whether these structural changes translate 
into a detectable morphological difference, the end-point aggregates were imaged by AFM. 
Both MmOLF and HsOLF samples show flat spherical oligomers ~ 6 nm in height and 1-
2 um in diameter (Figure 4.9). These species are similar in height, diameter, and circular 
morphology to our previous results for HsOLF using the same assay [36]. Still, the 
aggregates observed in these images are not identical. In the MmOLF sample there are 
additional curvilinear aggregates of varying length with similar height (~6 nm) to the 
spherical oligomers. The background of the HsOLF is more pronounced than that of 
MmOLF, perhaps suggesting long-lived smaller oligomeric species. Further studies, such 
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as AFM studies at different time points during aggregation, and systematic changes to the 
deposition surface, would be required to delineate the statistical significance of these 
differences. 
 
Figure 4.9 End-point aggregate morphologies of MmOLF and HsOLF. (A-C) Atomic 
force microscopy height imaging of samples post ThT aggregation confirm (A) a lack 
of aggregates in ThT-containing buffer control, while (B) HsOLF reveals spherical 
and curvilinear aggregates similar to (C) MmOLF. All images have a scale bar of 2 





Myocilin-associated glaucoma resembles other amyloid diseases like Alzheimer 
[119] in that numerous genetic mutations lead to a similar disease phenotype [92, 93]. From 
other well-studied amyloid systems, we know that specific amino acid substitutions, 
including naturally-occurring variants across species [120, 121] and disease-associated 
mutations [122-124], can lead to drastic changes in amyloid morphology and structural 
composition relevant to the severity of disease phenotypes. On the other hand, amyloid-
forming stretches with limited sequence similarity often exhibit similar aggregate 
structures [125], underscoring the complexity of biophysical principles underlying amyloid 
formation.  
In the case of myocilin, non-synonymous mutations in HsOLF result in a non-native 
protein that recruits properly folded myocilin into a template-assisted amyloid aggregation 
process [36, 37], leading to cell stress and death [13, 126-128]. In vitro, modifying 
parameters such as elevated temperature, low pH, slow agitation, and redox manipulation 
also access a partially-folded state of wild-type HsOLF, which in turn facilitates 
fibrilization [36, 37]. Other animals with with similar eye anatomy to humans [82] and 
mutations in the myocilin gene (e.g. monkey [129]) do not develop glaucoma, and robust 
phenotypes are not readily induced in mice [97, 99], prompting us to consider the 
possibility that myocilin homologs exhibit biophysical features that protect against 
aggregation or facilitate cellular degradation of aggregates.  
Previously, the leading explanation for the weak phenotype for mouse myocilin  
involved a putative cytosolic peroxisomal targeting sequence unique to HsOLF, proposed 
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to be exposed only upon misfolding [130]. HsOLF structures, however, reveal that the far 
C-terminal end of native HsOLF containing the suspected obscured signal sequence 
extends beyond the -propeller structural domain, in a fully solvent-accessible 
conformation in the native state [8], so the sequence is not hidden. Another proposed culprit 
for varied glaucoma phenotypes across murine myocilin glaucoma models is genetic 
background. Genetics are known to play an important role in eliciting a glaucoma 
phenotype in DBA/2J mice, which are predisposed to severe ocular-hypertension and RGC 
death [131]. Genetic backgrounds vary among the mice used to generate the currently 
available myocilin glaucoma mouse models, and could modulate phenotype severity [82, 
131]. Notably, adenovirus-induced overexpression of human Tyr437His myocilin resulted 
in elevated IOP in A/J, BALB/cJ and C57BL/6J mice, but not in C3H/HeJ mice [132]. 
Finally, mutant myocilin expression levels may influence resultant phenotypes. High 
expression appears important for an IOP elevation phenotype in available myocilin 
glaucoma mouse models. TM cells, like neurons, are long-lived and highly sensitive to 
protein misfolding, and may not require high levels of mutant myocilin to present aberrant 
phenotypes, but myocilin is present at relatively high concentrations in the cellular 
secretion studies [133-135] as well as in our experiments. Whether mutant myocilin 
overexpression is a general phenotype among myocilin glaucoma patients is currently 
unclear, but a recent histological analysis of a very rare sample of a glaucomatous donor 
eye harboring Tyr437His myocilin appears to support the finding that overexpression of 
mutant myocilin (relative to wild type levels in control eyes) is a factor [136].  
Our characterization of MmOLF structure and aggregation in this study, combined 
with prior cellular secretion studies demonstrating intracellular accumulation of selected 
 
 75 
mouse myocilin variants [133] to an extent similar to human disease-causing counterparts 
[12, 55], would predict a robust aggregation phenotype upon mutation in mouse. Namely, 
even though native structure and thermal stability are relatively unchanged, MmOLF 
aggregation kinetics are faster than HsOLF, which cannot be adequately explained by the 
two hydrophobic alterations found in the mouse P3 sequence. Increased ThT fluorescence 
seen for MmOLF could be attributed to charge or structural differences in the aggregate 
species [137]. Thus, one molecular level insight from our study is that differential surface 
electrostatics could be altering the aggregation profile of MmOLF. Compared to the largely 
negative HsOLF surface (calculated pI 5.0), the somewhat more neutral and varied 
MmOLF (calculated pI 5.8) is expected to exhibit faster initial aggregation, as seen in 
systematic studies of other model amyloid systems [138, 139]. Another molecular 
explanation could be the relative toxicity of the aggregates. There is an overall resemblance 
in endpoint morphology for MmOLF and HsOLF aggregates, but we know from other 
amyloid diseases that the intermediate aggregates are likely the neurotoxic species, not the 
final endpoint aggregate [140, 141]. Perhaps by aggregating more quickly, the putatively 
more toxic intermediate in MmOLF does not have time to populate, and instead is driven 
to the less toxic endpoint aggregate. Since OLF is a relatively new addition to the amylome, 
details of such intermediates including their structure and toxicity, as well as aggregation 
of OLF when tethered to a coiled-coil region by a long linker [9], remain open questions. 
Taken together, our findings motivate further work into dissecting the factors that elicit 
glaucoma in mice, to further support their use in glaucoma research.  
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CHAPTER 5. FUTURE DIRECTIONS. 
5.1 Introduction. 
This thesis encompasses advancements in 1) our understanding of popular 
commercial myocilin antibodies currently used as community standards, 2) the 
development of new, conformational antibodies to N-terminal myocilin and 3) the 
biophysical characterization of the mouse OLF domain which, alongside that of its human 
counterpart, and is a prerequisite to further OLF-targeted antibody development. Each of 
these studies is supported by prior developments in our structural understanding of 
myocilin itself and in in-vitro antibody selection and development technologies, and 
constitutes an exciting stepping stone for future research. These new antibodies are 
specifically tailored to address long-standing questions regarding myocilin function and 
dysfunction including identifying functional binding partners, post-translational 
modifications, and their contextual changes due to glaucoma. Does myocilin aggregate in 
the ECM after secretion and perhaps play a role in normal TM aging? Is in-vivo imaging 
of myocilin aggregates a feasible means of detecting glaucoma pathology prior to vision 
loss? And finally, is myocilin tractable for antibody therapeutics aimed at limiting the 
formation and accumulation of toxic aggregates? 
5.2 Optimization of Existing Antibodies.  
My thesis details the development of antibodies targeting N-terminal myocilin that 
possess a range of conformational specificity and cross-reactivity to mouse myocilin. 
Currently, the LZ-targeting IgGs 2A4 and 1G12 display strong affinity and cross-reactivity, 
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but the CC-targeting IgGs exhibit weaker affinity, less conformational specificity, and poor 
cross-reactivity to mouse. These attributes could be improved upon by 1) conducting 
additional immunizations with human CC33-111 and its mouse equivalent, 2) in-silico 
affinity maturation or 3) in-vitro affinity maturation. Affinity maturation efforts are already 
underway, by our collaborators, to further increase the power of IgG 2A4 (conformational 
& LZ-targeting) in downstream applications.  The optimized antibodies would be subjected 
to further characterization, including quantitative determination of binding affinity by 
surface plasmon resonance and application to further experiments, described in later 
sections.  
5.3 Development of OLF-Targeting Antibodies.  
Our collaborators in the Maynard lab have immunized mice with mouse and human 
OLF and extracted antibody libraries from their spleens in methods very similar to those 
described in Chapter 3. The existing commercial OLF antibody, besides lacking 
conformational specificity [35], exhibits weaker affinity relative to its N-terminal 
commercial counterparts. Therefore, initial panning of phage-displayed scFv antibody 
candidates should be conducted against folded and misfolded/denatured OLF to separately 
identify candidate conformational and linear antibodies with high affinity to mouse and 
human OLF. This approach is not an option for N-terminal myocilin domains as they 
unfold reversibly [9].  
Based on high sequence conservation within the interior of the β-propeller across 
OLF family members [8], one concern is that new OLF antibodies may exhibit binding to 
other OLF domains – a feature previously observed of commercial myocilin and noelin 
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antibodies [57]. Candidate OLF antibodies should be tested against other OLF family 
members expressed in the eye: optimedin, latrophilin, photomedin [142] and noelin [143]. 
Importantly, optimedin is known to colocalize with myocilin within the trabecular 
meshwork [144]. While noelin OLF can be produced by E. coli expression [57], 
mammalian cell expression of other OLF domains will be required.  
5.4 Anticipated Applications of New Antibodies  
5.4.1 Diagnostic and Therapeutic Applications of OLF Antibodies 
While the development of conformational antibodies specific to human and mouse 
myocilin will allow us to pull down folded myocilin to access N-terminal binding partners 
and to specifically track folded OLF domains in tissue samples, antibodies targeting 
specific misfolded OLF conformations are also of interest as potential diagnostics and 
therapeutics. Since glaucoma is largely painless and progresses gradually, an important 
clinical concern is finding means of detecting abnormalities prior to the onset of severe 
retinal and optic nerve damage [145]. It is estimated that by the time vision loss is observed, 
approximately 40% of RGCs are already dead [146], loss that could be prevented or 
considerably slowed by early treatment. As a complement to detection of RGC death in the 
back of the eye [146], detection of aggregate myocilin deposits in the trabecular meshwork 
could provide an even earlier warning of glaucomatous pathology. Antibodies demonstrate 
great promise for in-vivo imaging as biologically inert, high affinity and tunable markers 
of diverse species [147]. Antibodies to amyloid-beta and tau, which detect Alzheimer’s 
lesions in-vivo [148], provide exciting examples of diagnostic conformational antibodies 
currently under development for protein misfolding diseases. Similarly, circular and linear 
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fibril morphologies [36] and oligomers [37] of myocilin previously characterized by the 
Lieberman lab provide excellent targets for conformational antibody development.  
Such antibodies may also have therapeutic applications if they can remove 
aggregated myocilin, an approach to treatment which has shown promise in other protein 
misfolding diseases. For example, a number of antibody therapeutics currently under 
development seek to bind amyloid-beta fibrils, quench fibril elongation and facilitate 
clearance of the fibrils and oligomers whose accumulation is associated with Alzheimer’s 
disease progression [149]. Similarly, a structural understanding of the toxic forms of 
myocilin will guide a rational approach to arresting myocilin aggregation and enhancing 
aggregate clearance.  
5.4.2 Identification of Functional Binding Partners. 
Despite over twenty years of research there is no consensus as to the function of 
myocilin. Complicating this process is myocilin misfolding, which drives both self-
aggregation and interactions with chaperones such as Grp94 [150]. However, as with other 
OLF family members, identifying binding partners is key to determining myocilin function 
within the trabecular meshwork. The oligomeric state of endogenous myocilin likely plays 
a key role in spacing myocilin domains and their interacting partners and in increasing the 
avidity of binding interactions – features which appear to have foiled our own attempts to 
identify binding partners using individual recombinant domains of myocilin.  
The new N-terminal-targeting and future OLF-targeting myocilin antibodies offer 
an exciting solution to this problem through selective immunoprecipitation of well-folded 
endogenous myocilin from spent media of human trabecular meshwork cells. Such 
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antibodies should allow us to identify functional binding partners. Using multiple 
antibodies targeting different epitopes and domains within myocilin will help ensure that 
our antibodies are not excluding binding interactions to different regions of the protein. 
Additionally, these samples could be used to confirm myocilin post-translational 
modifications such as glycosylation, phosphorylation, and thereby gain insight into 
changes caused by the steroid and mechanical stress conditions associated with glaucoma. 
5.4.3 Visualizing myocilin conformations in biological context.  
Applying our antibodies to histology would allow tracking of multiple myocilin 
structural domains in various states of folding/misfolding in tissue samples. Of additional 
interest is detecting extracellular myocilin aggregates within the trabecular meshwork, 
which would indicate a role for myocilin the larger context of eye aging. Professor 
Lieberman is already in correspondence with experts in the broader glaucoma field who 
have professed interest in applying our antibodies to human and mouse tissues. Outside of 
gaining a more detailed picture of myocilin localization, these partnerships can give us key 
feedback to further improve our antibody reagents and will promote awareness of their 
availability throughout the broader glaucoma research community.  
5.4.4 Obtaining high-resolution insight into N-terminal myocilin structure. 
Fragments of these antibodies, e.g.  Fab, could serve as crystallization chaperones 
to allow us to further elucidate the structure of N-terminal myocilin by X-ray 
crystallography. Of particular interest would to explicitly capture the Y-shaped tetrameric 
assembly formed by the myocilin’s N-terminal coiled-coil and leucine dipper domains, 
including the N-terminal coiled-coil which so far have has eluded crystallization, lending 
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molecular level insight to the domain structure and the role of Cys47 and Cys61 disulfides. 
This structure could guide further antibody development (for example, as a potential 
starting point for in-silico affinity maturation of conformational CC-targeting antibodies), 
but also give additional structural insight into potential extracellular matrix interactions 
and/or the role of myocilin’s coiled-coil domains. 
5.5 Conclusion.  
A modernized set of custom, recombinant conformational myocilin antibodies will 
help address broader concerns of antibody reproducibility and offer eye researchers a new 
set of tools to track myocilin. We anticipate that these antibodies will additionally help us 
to further characterize myocilin on a functional basis by helping to identify binding 
partners, and on a dysfunctional basis by differentially tracking various domains and 
conformations of myocilin. A deeper understanding of the role of myocilin within the 
trabecular meshwork will help shed light on the molecular-level workings of the trabecular 
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